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6ABBREVIATIONS
aa amino acid
ABC1 ATP-binding cassette transporter 1
ACAT acyl CoA:cholesterol acyl transferase
AcLDL acetylated LDL
Apo apolipoprotein
BSA bovine serum albumin
BTEE N-benzoyl-L-tyrosine ethyl ester
CAPS 3-(cyclohexenylamino)-1-propane-sulfonic acid
CE cholesteryl  ester
CL cholesteryl linoleate
CETP cholesterol  ester transfer protein
CHD coronary heart disease
d density
Da dalton
DMEM Dulbecco´s modified Eagle medium
FC free cholesterol
HDL high density lipoprotein(s)
HBP HDL binding protein
IDL intermediate density lipoprotein
LCAT lecithin:cholesterol acyltransferase
LDL low density lipoprotein
Lp lipoprotein
LpAI lipoproteins containing apoAI
LpAI w AII lipoproteins containing apoAI and apoAII
LpAI w/o AII lipoproteins containing apoAI but not apoAII
LpAII w/o AI lipoproteins containing apoAII but not AI
MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight
MMP matrix metalloproteinase
m/z mass over charge
NMRI Nordic Medical Research Institute
PAGE polyacrylamide gel electrophoresis
PAGGE nondenaturing polyacrylamide gradient gel electrophoresis
PBS phosphate-buffered saline
PL phospholipid
PLTP phospholipid transfer protein
RCT reverse cholesterol transport
SDS sodium  dodecyl sulfate
SR-BI scavenger receptor class B type I
TG triacylglycerols
TIMP tissue inhibitor of metalloproteinases
VHDL very high density lipoprotein
VLDL very low density lipoprotein
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INTRODUCTION
    Epidemiological studies have shown that a low level of high density lipoprotein (HDL) cholesterol is a
powerful and  independent risk factor  for premature coronary heart disease (CHD) (Genest et al., 1999).  A
low HDL cholesterol  level  is associated  with an increased risk of  CHD even with a normal (<5 mmol/l)
total plasma cholesterol level. The mechanism whereby HDL imparts protection against premature
atherosclerosis is still  not completely understood. It is widely supposed, however,  that the protective role of
HDL is related to  its ability to remove cholesterol from peripheral cells.
     Peripheral cells obtain their cholesterol from a combination of synthesis and  uptake of cholesterol derived
mainly from low density lipoprotein (LDL). Reverse cholesterol transport (RCT) is the opposing movement
of cholesterol from peripheral cells through  the plasma compartment into the liver, where part of the cholesterol
is recycled in newly secreted  lipoproteins,  but part is excreted from the body in the bile as free cholesterol or
bile acids (Glomset, 1968). Although  RCT is the  only known process that can reduce the amount of excess
cholesterol in arterial tissue, the role of HDL in this process and how the process is modulated  are not fully
understood because of the difficulty of studying the complex metabolic pathways of HDL.
    HDL is a very heterogeneous mixture of particles and can  be fractionated into discrete, but overlapping,
subclasses by various techniques (Tailleux and Fruchart, 1996). These subpopulations may differ in their
metabolic, functional, and clinical significance. The main apolipoprotein in HDL is apolipoprotein (apo) AI,
which represents approximately 70% of the total apolipoprotein of HDL and is present in 90% of HDL
particles. ApoAI is suggested to have the key role in the antiatherogenicity of HDL.
    A  central feature of the pathology of atherosclerosis is the formation of macrophage foam cells (Brown
and Goldstein, 1983). Macrophages differ from typical peripheral cells in their ability to accumulate cholesterol
in the form  of cholesteryl  esters. In peripheral  cells,  de novo synthesis of cholesterol and LDL-cholesterol
uptake are  under tight negative feedback control,  which prevents cholesterol from accumulating  intracellularly.
Macrophages,  in  contrast, express scavenger receptors that are not regulated  by the intracellular cholesterol
level. Thus, modified LDL is taken up via scavenger receptor-mediated and other unregulated processes,
depending on its extracellular concentration. When the extracellular concentration of modified LDL is high,
the  macrophages accumulate cholesterol,  which  is stored in the cytoplasm as droplets of  the ester, which
give the cells a foamy appearance. Consequently, macrophages are heavily dependent on cholesterol  efflux
to prevent such accumulation of  lipids.  Insufficient  cholesterol  efflux may  be a consequence of  inadequate
movement of  intracellular cholesterol, too low HDL concentration in the extracellular fluid, or impaired
ability of these particles to accept cholesterol. This series of studies investigated  whether the proteases
present in  the aortic intima could impair the HDL-mediated efflux of cholesterol from macrophage foam
cells. In addition to answering the main question of what contribution the intimal proteases make to foam cell
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formation by decreasing HDL-mediated cholesterol efflux, proteolytic modification of HDL particles may
also provide information about the HDL subpopulations involved in the initial steps of reverse cholesterol
transport.
10
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REVIEW OF THE LITERATURE
1. Lipoproteins, atherosclerosis, and reverse cholesterol transport
   Cholesterol is an essential component of cell membranes and a precursor of bile acids and steroidal hormones.
Cells can synthesize cholesterol de novo and can take up exogenous cholesterol. Cholesterol is not water-
soluble; in the circulation it is packaged with triacylglycerols into carrier particles, the plasma lipoproteins
(Table I). Lipoproteins have a hydrophobic core of triacylglycerols and cholesteryl esters covered with a
hydrophilic surface of free cholesterol, phospholipids, and apolipoproteins. Lipoproteins can be divided into
six density classes: chylomicrons, very low density lipoprotein (VLDL), intermediate density lipoprotein
(IDL), LDL, HDL2, and HDL3.  In humans, LDL is the main cholesterol carrier in the circulation, and it is
mostly LDL which, via LDL receptor-mediated uptake, delivers cholesterol to the peripheral cells (Brown et
al., 1981). LDL uptake and de novo synthesis of cholesterol are under tight negative feedback control in the
tissues (Brown and Goldstein, 1986).
      LDL enters the arterial intima by transcytosis through the endothelial layer (Vasile et al., 1983). LDL is
retained in the intimal space through interactions with proteoglycans and other matrix components, which
lead to a high lipoprotein concentration in the intimal extracellular space (William and Tabas, 1995). In the
        Composition (mass %)  
               Lipid
Fraction Diameter Density
Apolipo-
proteins
Protein TG PL CE FC
     nm g/ml
Chylomicrons  75-1200 <0.95 AI,II,IV; B-48;
 CI,II,III; E
1-2 88 8 3 1
VLDL   30-80 0.95-1.006 B-100;CI,II,III;
E
   11 54 15 14 6
IDL   25-35 1.006-1.019 B-100; CI,II,III;
E
18 31 22 23 6
LDL   18-25 1.019-1.063 B-100 25 3 21 42 9
HDL2    9-13 1.063-1.125 AI,II,IV;
CI,II,III; D; E
43 2 30 20 5
HDL3    7-9 1.125-1.21 AI,II,IV;
CI,II,III; D
55 1 25 16 3
Modified from Fielding and Fielding, 1991
Table I. Composition of the lipoproteins in human plasma
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interstitial fluid the concentration of cholesterol is about 1/10 of that in plasma, but in the intimal fluid the
cholesterol concentration is double that in the plasma (Smith, 1990). The long retention time of LDL in the
intima exposes it to modifications, such as oxidation (Witztum et al., 1994). This modified LDL attracts
monocytes from the circulation into the intima (Rajavashisth et al., 1990; Nelken et al., 1991; O’Brien et al.,
1993). Monocyte-derived macrophages scavenge the modified LDL (Brown and Goldstein, 1983). The
scavenger receptors of macrophages are not regulated by the intracellular sterol content and, when the
extracellular content of modified LDL is high, macrophages may overaccumulate cholesterol. The cells become
filled with cholesteryl ester droplets, giving the cytoplasm a foamy appearance under the microscope, which
accounts for the term foam cell. Further overaccumulation of cholesterol may eventually lead the cells to
break down, releasing their cholesterol contents and cell debris into the extracellular space. In addition to
their activity as scavengers of modified LDL, macrophages also have an important function in secreting
inflammatory agents (Ross, 1999). Macrophages play an important role in the development and progression
of atherosclerotic lesions, and it is likely that many of their roles are influenced by their cholesterol-loaded
state (Tabas, 1995). Consequently, more monocytes are attracted from the circulation and the process is
accelerated. Foam cells form fatty streaks, which are the first hallmark of atherosclerosis (Stary et al., 1995).
Fatty streaks are common even in young adolescents but are still reversible and thus do not necessarily lead
to severe atherosclerosis.
   Fatty streaks initially consist of lipid-laden macrophages (Stary et al., 1995). Later, they are joined by
varying numbers of smooth muscle cells, which have migrated from the medial layer. In the atheroma, a
dense accumulation of extracellular lipids (the lipid core) occupies an extensive, but well-defined, region of
the intima. Formation of the lipid core precedes an increase in fibrous tissue that will subsequently change the
nature of the intima above the lipid core (fibroatheroma or fibrous plaque). The fibrous tissue consists
mainly of collagen (Stary et al., 1995). In intermediate and advanced lesions the core shows to a tendency to
necrotize. The necrotic core results from apoptosis and necrosis of macrophages and smooth muscle cells and
comprises cell debris and lipids (Björkerud and Björkerud, 1996). In an advanced lesion, the lipid core and
other parts are calcified (Wexler et al., 1996). Consequently, the artery wall is thickened and the lumen of the
vessel is narrowed. Thereafter, ulceration of the fibrous plaque or rupture of the fibrous cap, which usually
occurs in the shoulder regions of the plaque, can rapidly lead to thrombosis.
   Reverse cholesterol transport is the process whereby cholesterol is transported from the peripheral
(nonhepatic) cells to the liver (Glomset, 1968). Its extracellular route consists of four main steps: (i) efflux of
cholesterol from the cell membranes to HDL in the interstitial fluid, (ii) esterification of HDL-cholesterol by
lecithin:cholesterol acyltransferase (LCAT) in the bloodstream, (iii) transfer of cholesteryl esters from HDL
to other plasma lipoproteins by the cholesterol ester transfer protein (CETP), and (iv) delivery of these
cholesteryl esters to the liver (Fielding and Fielding, 1995a; Barter and Rye, 1996b). LCAT catalyses the
synthesis of cholesteryl esters and lysolecithin from the lipoprotein lecithin and free cholesterol. By increasing
12
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the cholesteryl ester content and thus decreasing the free cholesterol in HDL, it maintains a cholesterol
gradient from the cells to HDL. Two other lipid transfer proteins, phospholipid transfer protein (PLTP) and
CETP, contribute further to HDL remodeling. PLTP supplies lecithin to HDL and CETP exchanges the
cholesteryl esters formed by LCAT with the triacylglycerols of other lipoproteins, particularly VLDL and
LDL.
    The liver removes cholesterol brought to it from the extrahepatic tissues via several different mechanisms
(Tall, 1998). Firstly, the triacylglycerol-enriched HDL can be hydrolyzed by hepatic lipase, and thereafter
the unesterified cholesterol is transferred to the liver. Secondly, the HDL-derived cholesterol in the apoB-
containing particles is internalized by the apoB/E receptor. Thirdly, part of the apoB/E-receptor-mediated
hepatic uptake may consist of apoE-containing HDL particles. Fourthly, selective cholesteryl ester uptake
from HDL and LDL particles is possible via the newly discovered receptor, scavenger receptor class B type
I (SR-BI). The final step in the reverse cholesterol transport pathway is excretion of cholesterol from the liver
into the bile, either directly or after its conversion into bile acids.
   Epidemiological studies have shown that HDL and HDL cholesterol levels are inversely correlated with the
incidence of atherosclerosis (Stampfer et al., 1991). The antiatherogenesis of HDL is also supported by
animal studies: In transgenic mice, overexpression of human apoAI was associated with high levels of HDL
and was shown to reduce the progression of atherosclerotic lesions (Rubin et al., 1991). Overexpression of
human apoAI by somatic gene transfer to apoE knockout mice was associated with a two-fold increase in
HDL cholesterol and a two-fold decrease in the development of atherosclerotic lesions over a 6-week period
(Benoit et al., 1999). However, it is not excluded that the beneficial effects of HDL in preventing atherosclerosis
reside in factors that are not related to RCT, such as prevention of oxidation of LDL by HDL-associated
paraoxonase or prevention of induction of monocyte adhesion molecules (Barter and Rye, 1996a). However,
data reported by Dansky and coworkers (1999) suggest that elevated apoAI and HDL cholesterol inhibit
foam cell formation in apoE-deficient mice at a stage following lipid deposition (retention), endothelial
activation, and monocyte adherence, without increases in HDL-associated paraoxonase. The antiatherosclerotic
role of HDL in RCT is also supported by studies in which weekly injections of HDL or liver-directed gene
transfer of human apoAI resulted in significant regression of preexisting fatty streaks in cholesterol-fed
rabbits and in LDL-receptor-deficient mice, respectively (Badimon et al., 1990; Tangirala et al., 1999).
Moreover, infusion of pro-apoAI liposomes has been shown to promote net cholesterol excretion from the
body, implying stimulation of reverse cholesterol transport (Eriksson et al., 1999).
   Cholesterol transfer from the cell membrane to HDL, i.e. the initial step in extracellular reverse cholesterol
transport, is critical, since cells cannot catabolize cholesterol, and the only means by which intracellular
excess of cholesterol can be removed is cholesterol efflux. Impairment of this first step will especially affect
macrophages, in which cholesterol accumulates in atherosclerotic areas. In the heterogeneous mixture of
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HDL, certain subpopulations may have a more significant role as cholesterol acceptors than others. The
following sections will focus on aspects that concern the first step in RCT, cellular cholesterol efflux to HDL.
2. HDL structure
   HDL includes the densest (1.063-1.210 g/ml) and the smallest (7-12 nm) lipoproteins in the bloodstream
(Rye et al., 1999). In terms of particle number, HDL is the most abundant lipoprotein in the circulation; there
are 10- to 20-fold more HDL particles in the human body fluids than the number of all the other lipoprotein
particles together (Eisenberg, 1984). HDL is a highly heterogeneous mixture of particles and can be fractionated
by different techniques into discrete, but overlapping, subclasses.
Composition
   Like other plasma lipoproteins, the majority of HDL particles are spherical and consist of a hydrophobic
core of cholesteryl esters and triacylglycerols surrounded by a surface monolayer of phospholipids, unesterified
cholesterol and apolipoproteins (Tailleux and Fruchart, 1996). Some 3-5% of human HDL particles (preβ-
HDL) do not contain core lipids (Ishida et al., 1987). The mature HDL particles have masses ranging between
200 and 400 kDa. By weight, they consist of approximately 50% protein, 25% phospholipids, 20% cholesterol,
and 5% triacylglycerols; about 30% of the phospholipids consists of sphingomyelin.
     There are at least seven HDL-associated apolipoproteins: apo AI, AII, AIV, E, CI, CII and CIII (Tailleux
and Fruchart, 1996). Apolipoproteins are important for stabilizing the surface of the HDL particles and for
its various functions. ApoAI is the major protein in HDL, comprising about 70% of the total HDL protein
mass (Brouillette and Anantharamaiah, 1995). HDL apolipoproteins are exchangeable and a main characteristic
of their secondary structure is that they comprise a repeating amphipathic helical sequence (Segrest et al.,
1992). Apolipoproteins have internal repeats 11 residues in length, which in apoAI, apoAIV, and apoE have
evolved into multiple 22-mer repeats, usually starting with proline. These amphipathic helixes are half buried
in the lipid surface. The predicted conformation of these sequences indicates that one face of the helix is
largely occupied by nonpolar residues, while the other is largely occupied by charged residues. On the polar
face, charged residues are distributed in a characteristic pattern, negative ones in the center, flanked by
positive ones on either side. As proposed by Segrest and coworkers (1992), these alternating charges form ion
pairs with zwitterionic phospholipids, while lipid acyl chains are stabilized by alignment along the nonpolar
face.
   Enzymes important to reverse cholesterol transport, LCAT, PLTP, and CETP, are associated with HDL, as
well as such proteins as apoD, apoF, apoH, and apoJ, serum amyloid A, paraoxonase, and lipopolysaccharide-
binding protein (Schmitz and Williamson, 1991).
14
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Apolipoproteins
   Lipid-free apoAI originates in the liver and the small intestine (Barter and Rye, 1996a). It is a major
component of HDL; more than 90% of HDL particles contain apoAI (Brouillette and Anantharamaiah,
1995). In its mature form, apoAI is a 243-amino-acid protein with a molecular weight of 28 kDa (Brewer, Jr.
et al., 1978; Brouillette and Anantharamaiah, 1995). As mentioned above, it consists mainly of 22-amino-
acid-repeating segments typically spaced with helix-breaking proline residues. It has been suggested to have
one or more amphipathic α helical segments that undergo conformational changes to produce alternate
lipoprotein-bound and -unbound conformations. These hinged domains have been hypothesized to regulate
the size of the lipoprotein particles and the process of conversion of nascent discs to mature spheres (Segrest
et al., 1992). Computer analysis, in combination with studies using monoclonal antibodies and limited
proteolysis of apoAI, suggests that the region comprising helixes 5 and 6 (between aa residues 99 and 143)
may be the location of a flexible hinged domain in both soluble and lipid-bound forms of apoAI (Brouillette
and Anantharamaiah, 1995). The carboxyl terminus of apoAI (aa residues beyond 187) seems to be the
region with the highest affinity for lipids and the generally accepted view is that this region is important for
anchoring apoAI to the HDL particle.
    ApoAII is the other major apolipoprotein in HDL, representing approximately 20% of the total apolipoprotein
of HDL. Its molecular weight is 8.5 kDa, and it is linked by a disulfide bond to form a homodimer (Brewer
et al., 1972). ApoAII has a higher affinity for lipid than apoAI, and the apoAI in HDL is easily replaced by
apoAII (Mao et al., 1977).
     ApoAIV (46 kDa), ApoE  (34 kDa), and apo CI, II, and III (5.8, 9.1, and 8.8 kDa, respectively) are minor
apolipoprotein constituents of HDL (Tailleux and Fruchart, 1996). In fasting plasma, apoAIV is found in
HDL and in the lipoprotein-deficient plasma fraction. ApoE has three major isoforms.
Subfractions
     HDL can be fractionated by various methods based on density, size, apolipoprotein content, or charge. By
ultracentrifugation, human plasma HDL can be divided into two main classes (Eisenberg, 1984): HDL2
(1.063-1.125 g/ml; 9-13 nm; 400 kDa) and HDL3 (1.125-1.21 g/ml; 7-9 nm; 200 kDa). In addition, a third
subfraction can be isolated, very high density lipoprotein (VHDL; 1.21-1.25 g/ml), which is denser. Human
plasma also contains a small amount of apoE-rich HDL1, which is lighter but larger than HDL2.
      Nondenaturing polyacrylamide gradient gel electrophoresis (PAGGE) has been used to separate HDL on
the basis of particle size. Human plasma HDL includes five subclasses known as HDL2b, HDL2a, HDL3a,
HDL3b, and HDL3c in order of decreasing particle size (Nichols et al., 1986).
    Selected immunosorption techniques have been used to isolate subpopulations of HDL on the basis of their
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apolipoprotein content. One subpopulation of HDL contains, as its main apolipoproteins, apoAI and apoAII
(LpAI w AII), while, in another, apoAII is absent (LpAI w/o AII) (Cheung and Albers, 1984). Subpopulations
containing apoAII without apoAI  (Lp AII w/o AI) (Bekaert et al., 1992) and apoAIV with or without apoAI
(von Eckardstein et al., 1995b) are also found in plasma.
     Agarose gel electrophoresis separates HDL into preα-, α-, and preβ-mobility HDL, according to their
different charges (Kunitake et al., 1985; Asztalos et al., 1993). In normolipidemic plasma, the preβ-migrating
fraction of apoAI represents 3-5% of the total apoAI (Ishida et al., 1987). By combining agarose gel
electrophoresis with nondenaturing PAGGE (2D-PAGGE), preβ-HDL can be further separated into three
fractions, preβ1-, preβ2-, and preβ3-HDL (Castro and Fielding, 1988). Preβ1-HDL has an apparent molecular
mass of 60-70 kDa and a diameter of 5-6 nm  (Fielding and Fielding, 1995a). It contains the apoAI molecule
as the sole protein and has a lipid content of 10-40% (Table II). Lecithin and sphingomyelin are present in an
equimolar ratio. Discoidal preβ2-HDL contains three apoAIs per particle as the only apolipoprotein, with a
molecular mass of about 325 kDa (Castro and Fielding, 1988; Barrans et al., 1996). Preβ3-HDL is thought
to be the product of the interaction between LCAT and preβ2-HDL. Additionally, it contains apolipoprotein
D and CETP (Francone and Fielding, 1990). The proposed structural differences in apoAI in these particles
were summarized by the Fieldings (Fig. 1) (Fielding and Fielding, 1995a): Studies of monoclonal antibodies
suggest that, in preβ1-HDL, apoAI has a unique conformation in comparison with that in the other forms of
  Table II. Chemical composition of preβ-mobile subfractions
Protein FC PL CE Isolation methods Reference
             % of particle weight
Total
preβ*
91.3 0.3 6.6 1.8 Plasma: Anti-apoAI-
immunoaffinity
column, strach
electrophoresis, and
electroelution
(Kunitake et
al., 1985)
Preβ1** 47.5–8 7.6–2.3 44.0–4.6 absent Plasma:2D-
PAGGE, 
followed  by
lipid extraction
(Castro and
Fielding,
1988)
Preβ2** 21.5–4.3 5.7–1.0 73.8–2.6 absent
Preβ1** 67.6–2.3 1.3–0.4 22.5–3.1 7.2–1.5 Human follicular
fluid: agarose
electrophoresis,
electroelution, and
gel filtration
(Jaspard et al.,
1996)
*Determined as total protein
**Determined as apoAI
Modified from Barrans et al., 1996.
16
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HDL. Computer modeling of discoidal preβ2-HDL suggests that the repeating 22 amino-acid-residue helices
of apoAI run from side to side of the disc. Alternatively to this “picket-fence” model, a “belt” model, in which
the helices are oriented parallel to the bilayer surface, has been proposed for small discoidal HDL (Koppaka
et al., 1999). In contrast, in α HDL, the repeated sequences of apoAI are disordered; beta turns from the
different apoAI molecules may be in contact with each other on the surface of the sphere.
Figure 1. ApoAI structure in lipid-poor, discoidal, and spherical HDL
The conformation of preβ1-HDL differs from that in other HDL. It has an apparent molecular mass of
60-70 kDa, a diameter of 5-6 nm and lipid content of 10-40%. When the phospholipid and cholesterol
content increases, apoAI forms a disc with lipids (preβ2-HDL). Next, LCAT, apoD, and CETP are
associated with preβ2-HDL and this complex has preβ3-HDL mobility. LCAT esterifies free cholesterol,
forming mature cholesteryl ester core-containing particles (α-HDL), which are the major HDL particles
in plasma. Modified from Fielding and Fielding (1995a)
   As summarized by Barrans and coworkers (1996), all these observations highlight the complex
remodeling of HDL particles during their intravascular transit and demonstrate the great plasticity which
must be a major feature of apoAI, allowing it to maintain its association with the highly diverse
configurations and compositions of HDL particles.
                                                                                                                                               17
Review of the literature
3. Cholesterol transfer from cells to HDL
Cellular cholesterol homeostasis in macrophages
     Cholesterol is an essential structural element of all the plasma membranes of all cells. Cells obtain cholesterol
by internalization of intact lipoprotein particles, notably via the high affinity LDL receptor (Brown and
Goldstein, 1986). Selective uptake of free cholesterol from plasma lipoproteins and selective uptake of
cholesteryl esters from HDL and LDL are also possible (Fielding and Fielding, 1997). In addition, all nucleated
cells can synthesize cholesterol de novo. Within cells, free cholesterol can have three fates; it can be incorporated
into membranes, be effluxed to cellular acceptors, or be converted into cholesteryl esters. Further, hepatocytes
and enterocytes can excrete cholesterol into bile as cholesterol or bile acids and adrenal and gonadal cells can
use cholesterol as a substrate for steroid hormone production. In nonsteroidogenic peripheral cells, cholesterol
synthesis and influx are under tight negative feedback control and these cells have a small pool of cholesterol
esters.
   Macrophages and some types of vascular smooth muscle cell, which express scavenger receptors, are
exceptions, in that they can store large amounts of cholesteryl esters. Exogenous cholesterol can be delivered
to macrophages by receptor-dependent pathways: in addition to an LDL (apoB/E) receptor that binds native
LDL, macrophages have scavenger receptors of at least two classes which recognize modified LDL; one
recognizes both acetyl and oxidized LDL and the other recognizes only oxidatively modified LDL (Brown
and Goldstein, 1983; Brown and Goldstein, 1986; Sparrow et al., 1989). Furthermore, LDL-proteoglycan
aggregates and soluble modified LDL-antibody complexes are possibly internalized by scavenger receptors.
A major difference, compared to the apoB/E receptors, is that cell sterol levels do not down-regulate the
expression of scavenger receptors (Brown and Goldstein, 1983). In addition, neither LDL receptor-related
protein nor VLDL receptors, which internalize triacylglycerol-rich lipoproteins, are downloaded by cholesterol
(Ylä-Herttuala, 1996). Uptake of cholesterol into macrophages also occurs independently of lipoprotein
receptors, e.g. via phagocytosis of cell debris, large LDL aggregates, or cholesteryl ester-rich lipid droplets
(Hoff et al., 1990). In addition, myeloperoxidase-generated reactive nitrogen species convert LDL into a
form that is avidly taken up by macrophages (Podrez et al., 1999). Consequently, macrophages exposed to
modified LDL overaccumulate cholesterol.
      Lipoproteins which have entered the macrophages via receptor-mediated endocytosis or phagocytosis are
delivered to lysosomes (Brown and Goldstein, 1983). In the lysosomes, their cholesteryl esters are hydrolyzed
to free cholesterol by acidic cholesteryl ester hydrolase. Practically all the studies of intracellular cholesterol
trafficking have been performed with cells other than macrophages, mainly with fibroblasts or Chinese hamster
ovary cells. The studies of these two different cells have revealed essentially similar results, and it is therefore
possible that the fundamental steps in intracellular cholesterol trafficking obey the same rules in macrophages
also. LDL-cholesterol that leaves the lysosomes is soon found in the plasma membrane (Brasaemble and
Attie, 1990). The route of movement has not been firmly established, but is probably transits through the
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trans-Golgi network (Neufeld et al., 1996). After cellular cholesterol levels have reached a critical threshold
in macrophages, i.e. when the capacity of the plasma membrane to hold cholesterol is exceeded, esterification
of mixed lipoprotein-derived and cellular free cholesterol is stimulated by ACAT in the endoplasmic reticulum,
leading to the formation of cholesteryl esters (Xu and Tabas, 1991). It is suggested, on the basis of studies
with Chinese hamster ovary cells, that, although the bulk of LDL-derived cholesterol appears to be effluxed
from lysosomes to plasma membranes, another pathway, which is independent of the plasma membrane,
delivers LDL-derived cholesterol to ACAT in the endoplasmic reticulum  (Underwood et al., 1998). Free
cholesterol is toxic to cells and therefore excess cholesterol is stored as cholesteryl esters in cytoplasmic
inclusions i.e. lipid droplets (Brown and Goldstein, 1983). It is these cytoplasmic lipid droplets that give the
cell its foamy appearance. These cholesteryl esters are substrates for neutral cholesteryl ester hydrolase, and
cellular cholesterol circulates in a constant futile cycle of hydrolysis and re-esterification. It is estimated that
the cellular cholesterol pool moves continuously between the plasma membrane and the endoplasmic reticulum,
ensuring constant delivery to the cell interior accompanied by efficient return (Lange et al., 1993).
   An obligatory part in intracellular cholesterol transport, which mediates cholesterol transport to the
extracellular acceptors, is the ATP-binding-cassette transporter 1 (ABC1) (Young and Fielding, 1999). ABC1
expression is upregulated in cultured macrophages by cholesterol loading with acetylated LDL (acLDL)
(Langmann et al., 1999). Mutations in the ATP-binding-cassette transporter 1 gene (ABC1) have been found
to cause Tangier disease (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Rust et al., 1999).
Apolipoproteins and HDL subfractions as cholesterol acceptors
Properties of acceptors
   Virtually all subpopulations of HDL and most HDL apolipoproteins are able to function as acceptors of
cell cholesterol, but some types of HDL are more efficient acceptors of cell cholesterol than others (Barter
and Rye, 1996b). Differences in size, and in protein and lipid composition are factors that determine the
capacity of the HDL particle to reach and accept cholesterol from the plasma membrane (von Eckardstein,
1996). The lipid composition of the acceptor particles is also an important factor for cholesterol efflux. The
fact that the cholesterol: phospholid ratio in the acceptor is less than one favors cholesterol transfer to the
acceptor (Johnson et al., 1991b). The size of the HDL particle is another factor that affects its ability to
promote cholesterol efflux. Small particles rapidly extract cellular cholesterol, probably because it is easy for
them to approach the cell surface, whereas large particles have a good capacity to adsorb and retain the
cholesterol (Rodrigueza et al., 1997).
    Conflicting results have been reported concerning the effectiveness of LpAI w/o AII and LpAI w AII in
promoting the efflux of cholesterol from cells. In some reports (Johnson et al., 1991a; von Hodenburg et al.,
1991), the two subclasses were equally effective in transferring cholesterol from Fu5AH hepatoma cells or
                                                                                                                                               19
Review of the literature
macrophages. In other reports (Barbaras et al., 1987; Fruchart and Ailhaud, 1992; Ohta et al., 1992), LpAI
w/o AII, but not LpAI w AII, was found to release cholesterol from murine adipocytes, bovine aortic cells,
and rat macrophages. Different incubation times or techniques for the isolation of lipoproteins from plasma
may explain the different results (Fielding and Fielding, 1995a). Recent findings confirm that LpAI w/o AII
are superior to LpAI w AII in promoting cholesterol efflux from cells: When apoAI was displaced progressively
by apoAII in HDL3, the efflux from Fu5AH rat hepatoma cells decreased as the proportion of AII increased
and finally was approximately 50% lower when the particles contained only AII (Lagrost et al., 1995).
Serum LpAI w/o AII also demonstrated a much greater association with cholesterol efflux from Fu5AH cells
than LpAI w AII (de la Llera Moya et al., 1994). 2D-PAGGE analysis showed that α-LpAI w/o AII took up
two to four times as much [3H]cholesterol as α-LpAI w AII (Huang et al., 1995a). These findings are
supported by the clinical observation that, in CHD subjects, LpAI w/o AII levels were decreased, while LpAI
w AII levels were unchanged (Puchois et al., 1987).
   The superiority of LpAI w/o AII to LpAI w AII is not clearly understood. There is a broad specificity
associated with the removal of cellular phospholipids and cholesterol by the different exchangeable
apolipoproteins such as human apoAI, AII, AIV, E, and also insect apolipophorin III (Hara and Yokoyama,
1991; Hara et al, 1992). In contrast, apoCIII and monomeric human apoAII have no activity. Thus, it appears
that, to be able to promote cholesterol efflux from cells, apolipoproteins require at least four amphiphilic
helices per molecule. Model helix peptides that mimic the physical properties of amphiphilic helical segments
of apolipoprotein also show cholesterol-efflux promoting ability when they comprise at least two helixes
(Mendez et al., 1994; Yancey et al., 1995). Probably, cooperation between two or more helical repeats is
required for the cholesterol-promoting-activity of apolipoproteins (Oram and Yokoyama, 1996).
   Anti-apoAI antibodies and limited proteolysis of apoAI have been used to gain information about sites in
apoAI that may regulate cholesterol efflux. Studies with limited proteolysis or using monoclonal antibodies
suggest that both the central region and the carboxyl terminus of apoAI are involved in cholesterol efflux.
Monoclonal antibodies against epitopes between aa residues 74 - 111, 140 - 150 or 149 - 186 of apoAI have
been demonstrated to inhibit cholesterol efflux (Banka et al., 1994; Luchoomun et al., 1994; Sviridov et al.,
1996a). Reconstituted HDL containing mutant apoAI (pro165→arg) is also defective in promoting cellular
cholesterol efflux (von Eckardstein et al., 1993). On the other hand, the C-terminal region between residues
187 - 243 and 222 - 243 has been shown to be important in promoting cholesterol efflux to lipid-free apoAI
(Sviridov et al., 1996b; Marcel and Frank, 1998; Gillotte et al., 1999). Further truncation to residues 150 and
135 fully restored the ability of apoAI to promote cholesterol efflux, suggesting exposure of a second lipid-
binding region when the C-terminal half of apoAI is absent (Sviridov et al., 1996b). The apoAI Nichinan
(Glu235→0) is another mutant associated with decreased cholesterol efflux (Han et al., 1999). The C-terminal
is suggested to influence the structure of the whole protein, since truncation of C-terminal residues 223 - 243
of lipid-bound apoAI reduced the helicity of the central region (Pyle et al., 1996).
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 Preβ-HDL
   Several studies have provided evidence that plasma preβ-HDL is generated by dissociating from the surface
of circulating α-HDL in a process that may be facilitated by plasma (Kunitake et al., 1992; Hennessy et al.,
1993; Asztalos and Roheim, 1995). The regenerating enzymes in plasma are CETP, PLTP, and hepatic lipase
(Clay et al., 1992; Liang et al., 1995; Pussinen et al., 1995). In the preβ-mobile particles generated from
HDL
 
by PLTP or hepatic lipase, apoAI has been shown to form 48 to 78% of the particle mass (Marques-
Vidal et al., 1997; Guendouzi et al., 1999). In addition, some fraction of plasma preβ-HDL may originate
from apoAI newly synthesized by the liver or intestine (Hamilton et al., 1976; Green and Glickman, 1981).
   As described by Castro and Fielding (1988), preβ1-HDL is the first acceptor of cell cholesterol in plasma.
Cholesterol is then found in preβ2- and preβ3-HDL and finally in α-HDL. Addition of monoclonal antibodies
unique to preβ1-HDL significantly inhibited the efflux of labeled cholesterol from fibroblasts to plasma
(Fielding et al., 1994). After incubation for 90 min at 37°C, the plasma preβ1-HDL level is reduced by about
75%, suggesting reassociation of components of preβ- with α-HDL (Kawano et al., 1993). On subsequent
incubation of this plasma with fibroblasts cholesterol efflux from the cells was found to be considerably
decreased. The shift from preβ- to α-HDL is prevented when LCAT activity is inhibited or when the cells are
incubated with plasma (Miida et al., 1992).
Lipid-free apolipoproteins
Lipid-free apoAI, apoAII-dimer, apoAIV, and apoE have all been shown to accept cell phospholipids and
cholesterol (Hara and Yokoyama, 1991; Bielicki et al., 1992). The lipids, together with the respective
apolipoprotein, were recovered in a fraction with a density of around 1.1 g/ml (Hara and Yokoyama, 1991;
Hara et al., 1992). These particles were relatively rich in cholesterol and sphingomyelin, thus resembling
preβ-HDL.
ApoE-  and apoAIV-containing HDL subpopulations
     ApoAIV has been shown to prevent atherogenesis in transgenic mice (Duverger et al., 1996). It may
participate in reverse cholesterol transport by promoting the removal of cellular cholesterol from cells and by
its ability to activate LCAT (Steinmetz and Uterman, 1985; Stein et al., 1986).
    ApoE has a dual function. It is essential for the clearance of remnant lipoproteins from the plasma by the
liver and it plays a role in cholesterol efflux from cells. ApoE is  synthesized by tissue macrophages as well
as by the liver (Basu et al., 1981) and this may increase the cholesterol efflux in macrophage-rich areas in the
absence of plasma-derived apolipoproteins (Zhang et al., 1996). ApoE-deficient mice are prone to
atherosclerosis, but apoE-deficient mice that expressed apoE only in macrophages had significantly less
atherosclerosis (Stein and Stein, 1999). It is reported that, in nonexpressing macrophages, adding exogenous
apoE does not enhance cholesterol efflux to the same extent as in those that express apoE endogenously (Lin
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et al., 1999). This may imply a role of apoE in intracellular cholesterol efflux.
   In addition to lipid-poor particles containing apoAI, lipid-poor particles containing apoE (γ-LpE) (Huang
et al., 1994) and apoAIV (von Eckardstein et al., 1995b) have been found in plasma and have been shown to
contribute to the removal of cholesterol from cells. Their role as plasma cholesterol acceptors may be especially
important in apoAI disorders (von Eckardstein et al., 1995a; von Eckardstein et al., 1995b).
   As summarized by Barter and Rye (1996b), there is a growing consensus that, in terms of effectiveness as
acceptors of cell cholesterol, LpAI w/o AII particles are superior to both LpAI w AII and LpAII w/o AI
particles and that preβ-LpAI particles and possibly γ-LpE particles are superior to α HDL particles.
Role of intracellular signals in HDL/apolipoprotein-mediated cholesterol efflux
   Evidence based on many reports suggests a role for HDL or apoAI in triggering signal transduction in cells.
The elements of a complete signal transduction system triggered by HDL have yet to be confirmed. The
interaction of HDL3 with cells activates phospholipases C and D, with a concomitant increase in diacylglycerol
(Walter et al., 1995) (Fig 2.). Accordingly, it has been shown that HDL triggers protein kinase C activation,
Figure 2. Possible model of HDL and cell signaling
After binding of HDL (a) to a receptor (R), phospholipases C and D (PLC, PLD) in the
plasma membrane (PM) are activated (probably via G-protein) resulting in phosphati-
dylcholine (PC) turnover as well as in phosphatidylinositol (PI) hydrolysis with a
concomitant increase (b) in diacylglycerol (DG). This activates (c) protein kinase C
(PKC), which in turn phosphorylates intracellular proteins. HDL/apoAI cell interaction
was shown to stimulate (d) phosphorylation of three phosphoproteins (pp) 80, 27, and
18, the last possibly being involved in HDL-mediated cholesterol efflux (e). Repro-
duced with permission from Fidge, J. Lipid Res. 40:187-201, 1999.
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and this is associated with stimulation of protein secretion or enhancement of translocation of intracellular
cholesterol to the surface (Mendez et al., 1991). Li and coworkers (1997) showed that protein kinase C
inhibitors reduced cholesterol efflux by apoAI without changing the cholesterol efflux occurring by aqueous
diffusion. Moreover, HDL/apoAI-cell interaction was shown to stimulate the phosphorylation of three
phosphoproteins, 80, 27, and 18, the phosphorylation of phosphoprotein 18 being dependent on intact HDL
(Garver et al., 1997). HDL has also been shown to stimulate calcium release (Pörn et al., 1991). In addition,
cyclic AMP treatment stimulated cholesterol efflux from macrophages (Sakr et al., 1999).
   It has been demonstrated that, in fibroblasts from patients with Tangier disease, HDL3-mediated mobilization
of cellular cholesterol is impaired (Francis et al., 1995). Tangier disease is caused by mutations in the gene
encoding ABC1, which mediates intracellular cholesterol transport to the outer leaflet of the plasma membrane
(Bodzioch et al., 1999; Rust et al., 1999; Young and Fielding, 1999). A defect in ABC1 blocks cholesterol
efflux from the cells, leading to intracellular accumulation of cholesterol esters. Serum deprivation, cholesterol
loading, and cyclic AMP treatment, which are associated with increased efflux of cellular cholesterol, also
result in increased expression of ABC1 messenger RNA in cultured fibroblast cells from normal individuals,
whereas apoAI decreases their expression (Lawn et al., 1999). Studies with Tangier fibroblasts also show
impaired coordinate formation of phosphatidic acid and diacylglycerols via phospholipases C and D and no
stimulation of calcium release in response to HDL3 (Walter et al., 1996; Drobnic et al., 1995).
Modifications of HDL
    Proteolysis of HDL3 by trypsin or pronase reduced its ability to promote cholesterol efflux from cholesterol-
loaded fibroblasts (Oram et al., 1991). This was a consequence of its reduced ability to bind to the plasma
membrane and transfer sterols from intracellular pools to the plasma membrane. Mild trypsin treatment
(<20%) was sufficient to produce a maximal decrease in cholesterol efflux (Mendez and Oram, 1997).
Reconstitution of trypsin-modified HDL with isolated apoAI or apoAII restored the cholesterol transport-
stimulating activity of the particles.
   Limited proteolysis of HDL with trypsin, staphylococcus V8 protease, or elastase yielded a major stable
peptide of 11-11.5 kDa (aa sequences between 1 and 90-100 residues) and a minor product at about 24 kDa
(aa residues 1-208) (Dalton and Swaney, 1993). Similarly, chymotrypsin, trypsin, elastase, and subtilisin
generated a major N-terminal fragment of 22 kDa from reconstituted HDL, as determined by electrospray
ionization mass spectrometry (Ji and Jonas, 1995). These results are in qualitative agreement with those
reported by Kunitake and coworkers (1990), who found that cleavage of human preβ-particles produced two
major products at about 26 kDa and 14 kDa. Thus, the C-terminal half of apoAI seems to be more susceptible
to proteolysis than the N-terminal half; residues 1 to 90-100 are usually protected from proteolysis. Moreover,
preβ-particles are more susceptible to proteolysis than bulk HDL (Kunitake et al., 1990). Resistance of the
N-terminus of apoAI is also seen in systemic amyloidosis, in which production and retention of the N-
                                                                                                                                               23
Review of the literature
terminal residues 1 to 90-100 of apoAI are suggested to be the result of proteolysis (Obici et al., 1999). On
the other hand, Lins and coworkers (1993) found the major product of cleavage by proteinase K, trypsin, and
pronase to be C-terminal 24 kDa fragment (aa residues 43-46 to 243).
    Other modifications besides proteolysis have been shown to affect HDL-mediated cholesterol efflux from
cells. Glycosylation of apoAI, achieving up to 40-50% reduction of free lysine residues, decreased intracellular
cholesterol efflux from cells by  25-40% (Duell et al., 1991). Oxidation of HDL decreased cholesterol efflux
from cells by affecting both apolipoproteins and lipids (Nagano et al., 1991; Bonnefont-Rousselot et al.,
1995). On the other hand, tyrosyl radical-oxidized HDL was shown to enhance cholesterol efflux by forming
apoAI-apoAII heterodimers (Wang et al., 1998).
Cell surface apolipoprotein binding sites
    Evidence of HDL-mediated signal transduction in cells and reports of HDL binding sites on cell membranes
involved in cholesterol efflux suggested the presence of interaction site(s) for HDL on the plasma membrane.
Trypsin treatment of HDL abolished its binding to the high-affinity binding site, but not to the low affinity-
binding site, on rat liver plasma membrane (Morrison et al., 1992). In another study, the high-affinity binding
site showed the same affinity characteristics as the lipid-free apoAI (Barbaras et al., 1994). Mild proteolysis
of the human fibroblast surface selectively inhibited the initial appearance of cellular cholesterol in the preβ-
HDL fraction (Kawano et al., 1993) or apoAI-mediated efflux, but had only a limited effect on the apparent
cellular cholesterol efflux to HDL and apolipoprotein-free lipid emulsion (Li et al., 1995).
   Several cell membrane-associated HDL proteins have been identified as candidates for the apolipoprotein
receptors involved in cholesterol efflux (Graham and Oram, 1987; Bond et al., 1991; Hidaka and Fidge,
1992; Hokland et al., 1992), and two, HDL binding protein (HBP, vigilin) and SR-BI, have been cloned
(McKnight et al., 1992; Acton et al., 1996). However, no evidence that would clearly identify any of these
proteins as a mediator in cellular cholesterol efflux has been obtained (Yokoyama, 1998). Expression of HBP
is increased by cholesterol loading of cells and its overexpression in cultured cells enhances HDL binding
(McKnight et al., 1992). HBP has been found in human atherosclerotic plaques, but not in the healthy
coronary intima (Chiu et al., 1997). However, HBP lacks the classic signal peptides and membrane-spanning
region that typify plasma membrane receptors and it is questionable how it can deliver signals to the cell.
   Another HDL-receptor candidate is a class of scavenger receptors called SR-BI, which has been shown to
bind HDL and promote cellular uptake of cholesteryl esters without internalization or degradation of apoAI
(Acton et al., 1996). It is expressed largely in steroidogenic tissues and in the liver. The human homologue of
rodent SR-BI, CLA-1 (CD36 and LIMPII analogous-1) has recently been cloned (Murao et al., 1997). It has
also been detected in foam cells in human aortic atherosclerosis (Hirano et al., 1999). SR-BI also promotes
cholesterol efflux, and enrichment of acceptor particles resulted in marked stimulation of cholesterol efflux
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from cells that had higher levels of SR-BI expression (Ji et al., 1997; Jian et al., 1998). SR-BI has been
shown to be essential for maintaining normal biliary cholesterol levels in mice (Trigatti et al., 1999).
   It is possible that binding sites for apolipoproteins are microdomains of the plasma membrane which,
because of their unique composition of lipids and proteins, bind apolipoproteins with higher affinity than and
different specificity from the bulk of the plasma membrane (reviewed by Fielding and Fielding, 1997 and
Rothblat et al., 1999). Of such microdomains, one type is the caveolae (Fielding and Fielding, 1997). These
are clathrin-free, detergent-insoluble invaginations of the plasma membrane, which are rich in cholesterol
and glycosphingolipids.  Caveolae contain one or more members of a family of cholesterol-binding proteins,
caveolins (Murata et al., 1995). A caveolin has a hydrophobic central region that is thought to anchor it to the
plasma membrane, leaving its N- and C-terminals free in the cytoplasm (Kurzchalia et al., 1994). Cholesterol
transport of both newly synthesized and low-density lipoprotein-derived free cholesterol to the cell surface is
accelerated in cells expressing caveolin (Fielding and Fielding, 1995b; Smart et al., 1996). SR-BI has been
shown to colocalize with caveolae (Babitt et al., 1997). Detergent-insoluble membrane fractions can also be
isolated from cells that do not express caveolae (Fra et al., 1994; Ahmed et al., 1997). They may have similar
effects in promoting cholesterol efflux.
Mechanisms of cholesterol efflux from cells
     Two main mechanisms of cholesterol efflux from cells have been proposed: in one model, cholesterol
diffuses from the plasma membrane through the aqueous layer to the acceptor particles. In the other model,
cholesterol efflux is mediated by apolipoproteins. The mechanism used for cholesterol efflux from cells may
depend on such factors as the cell type, the metabolic state of the cell, and the nature of the extracellular
acceptor.
     In the aqueous diffusion model, the key factor determining the rate and direction of net cholesterol flux is
the cholesterol: phospholipid ratio; cholesterol moves from membrane with a higher ratio to a membrane with
a lower ratio. Exchange of free cholesterol occurs not only between the plasma membrane and lipoproteins,
but also between the different lipoprotein classes (reviewed by Johnson et al., 1991b; Rothblat et al., 1992
and Rothblat et al., 1999). Aqueous diffusion of free cholesterol from the plasma membrane to HDL is
believed to operate in all cell types, but is viewed as relatively inefficient (Rothblat et al., 1999). Direct
contact between the plasma membrane and the acceptor is not needed, but cholesterol molecules desorp from
the plasma membrane, diffuse through the aqueous phase, and subsequently are incorporated into phospholipid-
containing acceptor particles. The rate-limiting step in this mechanism is desorption of cholesterol from the
plasma membrane. The rate of desorption is influenced by the cholesterol/phospholipid domain structure and
enrichment of the plasma membrane with cholesterol increases the efflux rates. As mentioned earlier, various
structural factors in the acceptor particle may influence the efficacy with which cholesterol is absorbed into
the acceptor particle. An acceptor particle of small size may increase its access to the cell surface in the
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extracellular matrix, so narrowing the traverse of cholesterol through the aqueous layer. In this model, LCAT
is an important factor, providing a constant cholesterol gradient from the cells to HDL. The SR-BI-mediated
cholesterol flux to HDL is due to HDL binding and potential SR-BI-dependent changes in the lipid organization
and composition of the microdomain (de la Llera Moya et al., 1999; Williams et al., 1999). This cholesterol
flux is bi-directional and net cholesterol movement between the SR-BI docked-HDL and the cells is generated
by a cholesterol gradient, as in aqueous diffusion. However, uptake of cholesteryl esters from HDL to the cell
by SR-BI needs low energy, indicating a nonaqueous pathway (Rodriguenza et al., 1999).
   The second mechanism requires the interaction of an apolipoprotein with the plasma membrane lipid or the
protein domain (reviewed by Oram and Yokoyama, 1996; Yokoyama, 1998 and Rothblat et al., 1999). In this
model, lipid-poor apoAI dissociates from HDL particles, interacts with the cell surface lipid, protein, or
lipid-protein domain, and picks up cholesterol and phospholipids. There is evidence that release of phospholipids
precedes the release of cholesterol to lipid-poor apoAI (Forte et al., 1993; Yancey et al., 1995). Alternatively,
lipid-poor apoAI (preβ-HDL) can acquire both phospholipid and cholesterol simultaneously
(microsolubilization) (Gillotte et al., 1998; Rothblat et al., 1999). A finite pool of about 1% of the plasma
membrane cholesterol is accessible for release by solubilization. The limited size of this cholesterol pool is
not due to lack of availability of apoAI, but rather to the restricted amount of phospholipid that is removed
from the plasma membrane. This process may involve such plasma membrane domains as caveolae and
detergent-insoluble domains. In addition, vesiculation of the plasma membrane has been observed, followed
by release of these vesicles into the culture medium of apoAI-treated cells (Forte et al., 1993).
    Lipid-poor apolipoproteins may serve as transporters (shuttles) for moving cholesterol away from the cell
surface (Rodrigueza et al., 1997; Rothblat et al., 1999). These initial acceptors subsequently transport this
cholesterol to larger lipoproteins that serve as cholesterol sinks. Thus, the presence of large and small acceptors
together can overcome intrinsic deficiencies in each, achieving a synergistic effect: small acceptors are efficient
at extracting cellular cholesterol, but have a low capacity, whereas large acceptors are inefficient, but have a
high capacity (Rodrigueza et al., 1997). When they act together, however, the small acceptors and large
acceptors can achieve a high efficiency and a high capacity.
    The recently found ABC1 transporter is located in the plasma membrane, potentially in cholesterol-rich
rafts and caveolae, and may directly participate in the transfer of cholesterol from the plasma membrane to
HDL (Lawn et al., 1999; Young and Fielding, 1999).
HDL subfractions in interstitial fluid
   Peripheral cells, including foam cells in the atherosclerotic lesion, are exposed to lipoproteins of the interstitial
fluid rather than to those of the plasma. Forty percent of a small HDL tracer containing two apoAI molecules
was distributed to the noncirculating compartment at the start of a turnover study, indicating that a significant
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amount of the body HDL is in the extravascular fluids (Colvin et al., 1999). The lipoproteins in plasma have
been studied extensively, but there is less information on those in the tissue fluids to which most peripheral
cells are exposed. The concentration of apoAI and apoAII in the lymph is approximately 15% of that in
plasma (Reichl, 1990). Lymph contains large amounts of apoE in addition to apoAI and apoAIV (Dory et al.,
1985). LCAT activity is inhibited in lymph because of an unusual conformation of apoAI in the discoidal
HDL population (Wong et al., 1992). All the discoidal HDL particles in lymph contain large amounts of free
cholesterol and phospholipids (Sloop et al., 1987). In addition, peripheral lymph lipoproteins are enriched in
sphingomyelin (Reichl and Sterchi, 1992).
   The distribution of particle size of apoAI-containing lipoproteins in lymph differs from that in plasma
(reviewed by Sloop et al., 1987, Reichl, 1990, and Reichl, 1994). In lymph a large proportion of the apoAI
is associated with large discoidal particles (Reichl et al., 1985), corresponding in size to HDL1 (Reichl,
1990). Because only apolipoprotein E can be synthesized in tissues other than the liver and intestine (Basu et
al., 1981), the other apolipoproteins found in interstitial fluids must originate from plasma infiltrate. The
permeability characteristics of the vascular endothelium are known to favor the passage of smaller particles,
indicating that the large apoAI-containing particles in the extravascular fluid are predominantly products of
extravascular remodelling of HDL (Renkin, 1977). Lymph also contains relatively higher proportions of
small-sized HDL particles (about the same size as albumin) than plasma (Reichl et al., 1985). The amount of
preβ-HDL represents 14% of the total apoAI in the peripheral lymph (Barrans et al., 1996). Some of the
HDL also migrates in the electrophoretic field with preα (Reichl, 1990). The largest and smallest apoAI-
containing lipoproteins in lymph are LpAI w/o AII-particles (Reichl, 1994).
   The aortic intimal fluid differs from the interstitial fluid of other tissues in protein concentration. The aortic
intima is devoid of lymphatic capillaries, and in addition to endothelial barrier on the vascular surface, the
intimal layer also has another ‘molecular sieve’ in the medial surface, the internal elastic lamina (Groszek and
Grundy, 1980; Smith, 1990). The concentration of HDL in the aortic intimal fluid is almost 40% of that in
plasma (Smith, 1990). Compared to plasma, aortic intimal fluid is reported to contain a relatively larger
number of particles migrating at a slower rate than the α position; 80% of these particles had a density
comparable to the VHDL subclass and contained only apoAI (Smith, 1990).
4. Mast cell proteases and matrix metalloproteinases in atherosclerosis
Mast cell proteases
   Mast cells are derived from pluripotent hematopoetic stem cells in the bone marrow (Li and Krilis, 1999).
Mast cell progenitors from the peripheral blood invade local tissues, where they differentiate into their mature
phenotypes. Mast cells are heterogeneous, each subtype being a consequence of the cytokine pattern present
in its microenvironment. In rodents, mast cells can be divided into two types: mucosal and connective tissue
type. In humans, this classification is not possible and the main criterion for mast cell subtypes is the content
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of the mast cell-specific proteases chymase and tryptase (Welle, 1997). The presence of a cathepsin G-like
protease was demonstrated in mast cells with chymase and tryptase, but not in mast cells with tryptase only
(Schechter et al., 1990). In atherosclerotic lesions of human coronary arteries, the number of mast cells is
increased (Stary, 1990). Mast cells of both subtypes are present in aortic and coronary intimas (Kaartinen et
al., 1994a). In the aortic intima mast cells amount to 3% of all nucleated cells in normal areas and fatty
streaks and in the coronary intima to 0.1 and 0.9% of all nucleated cells in normal areas and fatty streaks,
respectively (Kovanen, 1996). In atheromas, the density of mast cells is 5-fold higher in areas where foam
cells are present than in areas without foam cells. Their density is highest in the shoulder regions of atheromas
(Kaartinen et al., 1994b)
    The biological functions of mast cells, including their roles in allergy, inflammation, tissue remodelling,
and angiogenesis, result from biologically active agents called mediators which are released from the mast
cells after stimulation. The mediators in mast cells are of two types: mediators that are preformed and mediators
that are produced de novo when the mast cells are stimulated (Schwartz and Austen, 1984). Newly generated
lipid mediators synthesized from membrane phospholipids after mast cell activation include prostaglandins,
leukotrienes, and platelet-activating factor
 
(Harvima et al., 1994). The stored mediators include histamine,
heparin and chondroitin sulfate proteoglycans, and the neutral proteases tryptase, chymase, carboxypeptidase,
and cathepsin G (Welle, 1997). The dominant glycosaminoglycan in mast cells is heparin, with a mixture of
chondroitin sulfates (Metcalfe et al., 1980). Neutral proteases are stored in the secretory granules of mast
cells in an enzymatically active state, and often represent more than 50% of the total protein content of the
mature mast cells of the rat (Welle, 1997). Although the concentration of proteases in the granules is extremely
high, their binding to ser-gly proteoglycans and the low pH of the granules prevents their degradation (Huang
et al., 1998).
   Mast cells are stimulated by a wide variety of agents, including antigens and complement C3a and C5a
(Kokkonen and Kovanen, 1990). Macrophages and T lymphocytes also secrete agents that stimulate mast
cells. In the atherosclerotic areas, the proportion of mast cells that are degranulated in the shoulder regions is
high (85%) (Kaartinen et al., 1994b). During degranulation, the granules become swollen and their membranes
fuse to form the degranulation channels through which granules are exocytosed to the extracellular space
(Galli et al., 1984). Degranulation is a rapid and explosive secretory event, which is completed within minutes
of stimulation. After their exocytosis into the environment at pH 7.4, most mast cell proteases remain bound
to heparin proteoglycans by their positively charged domains, forming macromolecular complexes, the so-
called granule remnants (Schwartz and Austen, 1984). The interaction with proteoglycans may be important
in regulating substrate specificity, prolonging retention of the enzymes, and protecting them from inactivation
by protease inhibitors (Eklund and Stevens, 1993). The plasma protease inhibitors seem to inhibit mast cell
proteases incompletely (Schechter et al., 1989). Tryptase, when dissociated from heparin, breaks down from
the tetramer to monomers, and loses activity irreversibly (Schwartz et al., 1990). The eventual fate of the
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granule remnants is not known, but it has been shown that they can be phagocytosed and degraded by
numerous adjacent cell types (Lindahl et al., 1979; Baggiolini et al., 1982).
   Chymases are 28-30 kDa proteases which have chymotrypsin-like cleavage specificity. Rodents have several
chymases, but current data are consistent with the  existence of only one major chymase in humans (Welle,
1997). Mast cell chymases vary greatly in surface charge and in their binding to negatively charged heparin-
and chondroitin sulfate-containing proteoglycans. The chymases examined in the present study, human chymase
and rat serosal mast cell chymase, have net charges of +13 and +18, respectively, thus remaining bound to
proteoglycans after exocytosis (Eklund and Stevens, 1993). Chymase has a positively charged proteoglycan
binding face on the surface of the folded protease that faces away from the catalytic site (Sali et al., 1993).
The rat serosal mast cells used in the present studies contained not only chymase, but also carboxypeptidase
A (Eklund and Stevens, 1993). This is a 35 kDa exopeptidase which also remains bound to heparin
proteoglycans after exocytosis.
    The density of degranulated mast cells is highest in the shoulder regions of atheromas (Kaartinen et al.,
1994b). These areas also contain increased expression of matrix metalloproteinases (MMPs) (George, 1998).
Chymase and tryptase have been shown to convert the proenzymes of MMPs-1, -3 and -9 to their active
counterparts (Gruber et al., 1989; Saarinen et al., 1994; Fang et al., 1996). Chymase and tryptase by themselves
can also directly degrade extracellular matrix proteins (Vartio et al., 1981; Lohi et al., 1992).
   Studies with rat mast cells suggest a role for mast cells in LDL-derived cholesterol accumulation in the
intima both intra- and extracellularly. LDL binds via apoB to the heparin proteoglycans of granule remnants
(Kokkonen and Kovanen, 1989). LDL particles are proteolyzed by chymase, become unstable, and fuse with
each other. Because of this fusion, granule remnants are able to bind more LDL particles. Proteolysis also
strengthens the binding of LDL to granule remnants (Paananen and Kovanen, 1994). In cell culture studies,
granule remnants are phagocytosed by mouse and rat macrophages, and rabbit aortic smooth muscle cells
and foam cells are formed (Kokkonen and Kovanen, 1989; Ma and Kovanen, 1995; Wang et al., 1995).
Evidence for such granule-mediated uptake of LDL into macrophages and smooth muscle cells in vivo has
been found in electron micrographs of the human arterial intima (Kaartinen et al., 1995). Thus, proteolysis of
LDL by mast cell chymase may lead to modification of LDL that is proatherogenic. However, mast cells are
able to prevent another modification, i.e., oxidation of LDL (Lindstedt et al., 1993).
Matrix metalloproteinases
   The matrix metalloproteinase family comprises at least 19 zinc-dependent endopeptidases. These MMPs
all have the following features in common: (1) they degrade one or more components of the extracellular
matrix, (2) they contain Zn2+ at their active sites and require Ca2+ for stability, (3) they are secreted in a latent
proform (zymogen) requiring activation for proteolytic activity, (4) they function at neutral pH, (5) they are
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inhibited by specific tissue inhibitors of metalloproteinases (TIMPs), and (6) they share cDNA homology
(Martisian, 1990; Woessner, 1998). The last two criteria are the most important for distinguishing the matrix
metalloproteinase (matrixin) family from other metalloproteinases (Woessner, 1998). On the basis of their
domain structures and substrate specificity, MMPs are classically divided into subgroups: collagenases,
gelatinases, stromelysins, and stromelysin-like MMPs, and membrane-type MMPs which, unlike the others,
are attached to the cell surface. Very little is known about the specific in vivo substrates for the MMPs.
However, from in vitro analyses of protease activity, it is evident that, collectively, the MMP family can
degrade all known matrix components. Typical substrates of the subgroups in vitro are summarized in Table
III.
   MMPs are generally expressed at low levels in normal steady-state adult tissue, but the expression is up-
regulated during many normal and pathological remodeling processes (Woessner, 1998). The activity of
MMPs is tightly regulated (Dollery et al., 1995). Regulation operates at three levels: transcription, activation
of latent proenzymes, and inhibition of proteolytic activity.
   One of the early events in atherosclerosis is infiltration of circulating monocytes into the intima. Thereupon
a series of complex cell-cell interactions take place, involving  secretion of a wide variety of growth factors
and cytokines, such as platelet-derived growth factor, tumor necrosis factor alpha, and interleukin-1, which
are known to stimulate MMP expression in vitro in macrophages, smooth muscle cells, and some types of
vascular endothelial cells (Dollery et al., 1995). Elevated levels of MMPs –1, -2, -3, -7, -9, -12, -13, and -14
have been detected in atherosclerotic plaques in macrophage-rich areas (George, 1998; Rajavashisth et al.,
1999; Sukhova et al., 1999). Macrophage foam cells are mainly responsible for MMP production, but smooth
muscle cells, lymphocytes, and endothelial cells also express MMPs (Galis et al., 1994; Brown et al., 1995;
Halpert et al., 1996). Mere loading of macrophages with cholesterol has been shown to stimulate their MMP-
12 production (Matsumoto et al., 1998). Lipid-laden macrophages isolated from atherosclerotic plaque have
been shown to produce MMP-1 and MMP-3 constitutively (Galis et al., 1995).
   The aortic regions with higher MMP expression also exhibited gelatinolytic and caseinolytic activities,
suggesting that some, at least, of these enzymes were active (Galis et al., 1994; Johnson et al., 1998; Zaltsman
et al., 1999). The mechanisms of zymogen activation in vivo are not completely understood. Current evidence
suggests that the latency of the proenzyme is maintained by a putative cysteine-Zn bond (Van Wart and
Birkedal-Hansen, 1990). This is known as the ‘cysteine switch’ and depends on interaction of a conserved
cysteine in the propeptide with the zinc in the highly conserved catalytic site, so preventing access of the
substrate to the catalytic site. Cleavage of the propeptide destabilizes the zinc-cysteine interactions, and the
peptide bond between the propeptide and the catalytic domain of MMP is partially activated, leading to
cleavage of the remainder of the propeptide by the MMP itself or by other MMPs. This results in exposure of
the catalytic site to the substrate. Activation of the proenzyme forms of MMPs can be accomplished in vitro
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Nomenclature MMP Mass, kDa
Latent/active
Activated
By
Activates
MMP-
Substrate specificity
Collagenases Collagen types I-III
   Interstitial collagenase 1 52/42 Kallikrein, chymase,
plasmin, MMPs -3,
 -10
2
   Neutrophil collagenase 8 85/64 Plasmin, kallikrein,
elastase, cathepsin G,
trypsin , MMPs-3,-10
ND
  Collagenase-3 13 52/42 Plasmin, MMPs -2,
 -3, -10, -14
2, 9
Gelatinases
   Gelatinase A 2 72/66 MMPs -1, -7 ,-13-17,
24
9, 13
Collagen types IV,V;
elastin, proteoglycans
   Gelatinase B 9 92/84 Plasmin, MMPs -1,  -
2, -3, -7, -13
ND
Stromelysins Collagen types III-V,
laminin, fibronectin,
gelatin, proteoglycans
   Stromelysin-1 3 57/45 Trypsin, chymase,
plasmin, etc, not by
MMPs
1, 8, 9,
13
   Stromelysin-2 10 54/44 Plasmin, tryptase,
elastase, cathepsin G
1, 8, 13
   Stromelysin-3 11 64/46 Furin ND
Stromelysin-like MMPs The same as for
stromelysins, elastin
   Matrilysin 7 28/19 Trypsin, plasmin,
elastase, MMP 3,
2
   Metalloelastase 12 54/22 ND ND
Membrane-type MMPs Collagen type IV,
   MT1-MMP 14 66/54 Plasmin, furin 2, 13 Gelatin
   MT2-MMP 15 72/60 Furin 2, 13
   MT3-MMP 16 64/53 Furin 2
   MT4-MMP 17 57/53 Furin 2
Others
18/19 54/45
  Enamelysin  20 54/22
Note: this list is incomplete, representing only selected substrates. These substrates are a guide to
potential biological function, but the actual substrates in vivo are unknown.
Modified from K h ri and Saarialho-Kere, 1997, Ye et al., 1998; George, 1998 and Woessner, 1998 .
The list of MMPs is constantly growing and now includes also the following numbers: MMPs -21, -22,
-23, and -24 (MT5- MMP) (Gururajan et al., 1998, Pei, 1999, Velasco et al., 1999).
Table III. Mammalian matrix metalloproteinases
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by denaturants such as sodium dodecyl sulfate (SDS) and urea, oxidants, or organomercurial compounds
(Woessner, 1998). The effects of these compounds are considered to be due to disruption of the cysteine-zinc
bond, which allows autolysis of the enzyme.  Plasmin, chymase, and tryptase have been proposed as activators
of the MMPs in atherosclerotic plaques (George, 1998). Active MMPs can also activate each other. This
creates a complex network of proteases in the extracellular space. Evidence of the role of plasmin in vivo was
obtained from apoE/urokinase-type plasminogen activator knock-out mice, which are protected from destruction
of the medial elastic lamina, probably by means of reduced plasmin-dependent activation of proMMPs
(Carmeliet et al., 1997). In addition, Shipley and coworkers (1996) showed that metalloelastase (MMP-12)
of macrophages is required for macrophage-mediated extracellular matrix proteolysis and tissue invasion in
mice. The oxygen radicals released from macrophage foam cells may also be involved in MMP activation by
disrupting thiol reactions in the proenzyme (Rajagopalan et al., 1996).
   The active MMPs are inhibited by a family of specific inhibitors, TIMPs, and less specifically by α2-
macroglobulin and α1-antitrypsin (Kähäri and Saarialho-Kere, 1997). The TIMP family comprises four
members. They form high-affinity, essentially irreversible, noncovalent complexes with the active forms of
MMPs. In atherosclerosis, the expression of TIMPs -1, -2, and -3 is also increased, but only partly
counterbalances the increased MMP activity in the pericellular zones of macrophages (Fabunmi et al., 1998;
Zaltsman et al., 1999).
   MMPs have been postulated to take part in many pathological processes in atherosclerosis, such as infiltration
of monocytes, migration and proliferation of smooth muscle cells, angiogenesis, and plaque rupture (reviewed
by George, 1998). Rupture in the shoulder region of the plaque is frequently found to correlate with loss of
the extracellular matrix. The same regions are also found to accumulate macrophages (Lendon et al., 1991).
Local overexpression of MMPs at the sites of maximal circumferential stress (Chen et al., 1993) may cause
degradation of the extracellular matrix, which promotes plaque-weakening rupture. However, genetic
polymorphism of the promoter of MMP-3, which causes diminished expression, is associated with enhanced
progression of atherosclerosis and with smaller prevalence of acute myocardial infarctions (Ye et al., 1998;
Terashima et al., 1999). Reduced levels of MMP-3 expression have been postulated to contribute to a net
increase in matrix deposition, leading to more rapid chronic growth of the atherosclerotic plaque (Ye et al.,
1998).
   As indicated above, atherosclerotic areas show increased concentrations of mast cell proteases and matrix
metalloproteinases, which are also, at least partly, enzymatically active. Evidence of involvement of matrix
metalloproteinase has been obtained in several pathological processes in atherosclerosis. Accordingly, mast
cell proteases have been suggested to be involved in LDL cholesterol accumulation in the atherosclerotic
intima. However, no information is available concerning the role of these proteases in HDL metabolism and
its function as a cholesterol acceptor in the route of reverse cholesterol transport.
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AIMS OF THE PRESENT STUDY
   Macrophage foam cell formation is a characteristic occurrence in atherosclerosis. Foam cells are formed
when modified LDL is scavenged by macrophages, and this excess of modified LDL-derived cholesterol is
not sufficiently removed from the cells to acceptors. Insufficient cholesterol efflux from macrophages may be
a consequence of impaired intracellular cholesterol transport, an inadequate number of acceptor particles
(HDL), or impaired ability of these particles to effect efflux. Aortic intimal fluid contains metabolically
active factors such as proteases, which may act on HDL and impair its ability to accept cholesterol.
The specific aims of this study were to answer the following questions:
1. Could proteolysis of HDL by the two types of neutral proteases present in the human arterial intima, mast
cell chymase and matrix metalloproteinases (MMPs), reduce its ability to accept cholesterol?
2. Is some subpopulation of HDL more susceptible to proteolysis and what is the role of this subpopulation
as a cholesterol acceptor?
3. Does the major apolipoprotein component of HDL, apoAI, contain a domain(s) that is more susceptible to
proteases?
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METHODS
The biochemical and cell biological methods used in the original articles included in this thesis are summarized
in Table IV. Only the methods central to this thesis are described in detail.
 Table IV Biochemical and cell biological methods used in this study
1. Animals
   Male Wistar rats (300-500 g) were from the Laboratory Animal Center of the University of Helsinki, and
female NMRI mice (20-30 g) were purchased from a licensed animal center (Poikkijoki, Kuvaskangas,
Finland) or from the Viikki Laboratory Animal Center of the University of Helsinki.
Methods Original publications References
Preparation of mouse macrophage
foam cells
I-IV Ho et al., 1980
Preparation of human monocyte-
derived macrophage foam cells
II-IV
Preparation of plasma serum and aortic
intimal fluid
II,III Smith and Staples, 1982
Isolation of LDL and lipoprotein-deficient
serum
I-IV Havel et al., 1955; Radding and
Steinberg, 1960
Modification of LDL (acetylation) I-IV Basu et al., 1976
Radioactive labeling of LDL I-IV Brown et al., 1975;
McFarlane, 1958 and
Bilheimer et al, 1972
Carboxypeptidase A activity assay I Kokkonen et al., 1986
Histamine assay I Kokkonen and Kovanen, 1985
Protein assay I-IV Lowry et al.,1951
SDS-PAGE I-IV Laemmli, 1970
Cellulose acetate electrophoresis I-IV
Agarose electrophoresis I-IV
Determination of lipid peroxidation of HDL I Hessler et al.,1983
PLTP and CETP activities IV Jauhiainen et al., 1993
Determination of phospholipid content of
HDL
I
Determination of total cholesterol content of
HDL
I
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2. Preparation of mast cells and isolation of mast cell chymase
Preparation of rat mast cell suspensions and isolation of exocytosed mast cell granules (I-III)
   Serosal mast cells were isolated from peritoneal and pleural cavities of rats. The isolated mast cells were
stimulated to degranulate with compound 48/80 (Sigma). The exocytosed granules, i.e., granule remnants,
were isolated from the released material, as described (Lindstedt et al., 1992). The quantity of granule remnants
is expressed in terms of their protein content or chymase activity, using N-benzoyl-L-tyrosine ethyl ester
(BTEE) as substrate (Woodbury et al., 1981) with modifications (Kokkonen et al., 1986). Unit definition: 1
BTEE unit corresponds to a 0.001 increase in absorbance at 256 nm per min when 0.5 mM BTEE is used as
substrate, in 3 ml of 50 mM Tris-HCl, pH 7.4, at 25 °C. When proteolysis was not permitted, granule
remnants were inactivated with 250 µg/ml phenylmethylsulfonyl fluoride in 5 mg/ml BSA, 1mM EDTA,
5mM Tris-HCL, pH 7.4, or in macrophage cell culture studies with 0.1 mg/ml soybean trypsin inhibitor and
5 mg/ml BSA in medium A.
Isolation of chymase from rat mast cell granule remnants or human skin (II, III)
   Granule remnants were first resuspended in 10 mM phosphate buffer, pH 7.0, containing 2M KCl to
dissociate the chymase from the heparin proteoglycans (Kido et al., 1985), and the mixture was applied in the
same buffer to a Sephacryl S-200 column (1 x 50 cm; Amersham Pharmacia Biotech). Eluted fractions
containing chymase activity were diluted with 10 mM phosphate buffer to give a final concentration of 0.5 M
KCl, and applied in this buffer to a HiTrap Heparin column (1 ml, Amersham Pharmacia Biotech). The
chymase was eluted by increasing the concentration of KCl to 1 M, and stored in this buffer at -20 °C. Before
experiments, the chymase-containing fractions were diluted with 5 mM Tris-HCl, 1 mM EDTA, pH 7.4, to
give a final concentration of 150 mM KCl. Chymase from human skin was prepared as described (Saarinen
et al., 1994).
3. Matrix metalloproteinases and their activation (IV)
   Recombinant MMPs-3, -7, and -12, obtained from Dr. H. Welgus, were expressed as active forms and
purified as described before (Ye et al., 1992; Sires et al., 1994; Gronski et al., 1997). MMPs-1 and -9 were
purified (Sires et al., 1995) and activated with phenylmercuric chloride (Stricklin et al., 1983), and activities
were measured by the 14C-gelatinase assay (Harris, Jr. and Krane, 1972), one unit corresponding to degradation
of 1 µg of gelatin/min/µg enzyme at 37 °C.
4. Preparation of HDL lipoproteins, apolipoproteins, and apoAI-deficient serum (I-IV)
   Human HDL subfractions were isolated by combinations of ultracentrifugation (Havel et al., 1955; Radding
and Steinberg, 1960), size-exclusion chromatography, and immunoaffinity chromatography (Barbaras et al.,
1987). Similarly, apoAI-containing particles (LpAI) from serum were separated with an anti-apoAI-
immunosorbent column according to Barbaras and coworkers (1987). Apolipoproteins AI and AII were
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isolated from HDL (d=1.063-1.210 g/ml) by ethanol-ether extraction (Scanu, 1966), followed by separation
of apoAI and apoAII by anion exchange chromatography on a HiTrap Q column (Amersham Pharmacia
Biotech) (Mezdour et al., 1987).
5. Proteolysis of cholesterol-accepting particles
Proteolysis of acceptor particles by mast cell granule remnants (I-III)
   Acceptor particles were incubated at 37 °C for 6 h in the presence or absence of granule remnants (6 µg) in
300 µl of culture medium on macrophage foam cells. In some cases, the cholesterol efflux-inducing ability of
samples preincubated with granule remnants was determined. In pretreatments, HDL3 (0.6-1.0 mg/ml) was
incubated at 37 °C for 30-120 minutes in 50-100 µl of the 150 mM NaCl, 1 mM EDTA, 5 mM Tris-HCl, pH
7.4, with granule remnants  (containing 170 BTEE U/ml, corresponding to about 100 µg of granule remnant
protein /ml). Aortic intimal fluid was pretreated as follows: 2.5% of intimal fluid was incubated in the 150
mM NaCl, 1 mM EDTA, 5 mM Tris-HCl, pH 7.4, in the absence or presence of 0.05 mg/ml of granule
remnants at 37 °C for 18 h. After incubation, the granules were removed by centrifugation and the supernatant
was applied to the macrophage monolayers.
Proteolysis of apoAI by human chymase (III)
   ApoAI (0.6 mg/ml) was incubated with 100 BTEE units /ml of purified human skin chymase in 150 mM
NaCl, 1mM EDTA, 5 mM Tris-HCL, pH 7.4, at 37°C for 18 h.
Proteolysis of HDL3 by matrix metalloproteinases (IV)
   HDL3 (1.5 mg/ml) were incubated with MMP-1, -3, -7, -12 (each 20 µg/ml), or MMP-9 (40 µg/ml) in
300 µl of 200 mM NaCl, 10 mM CaCl2, 50 mM Tris, pH 7.6, in the presence of 0.02 mM butylated
hydroxytoluene at 37 °C for the indicated time periods. Proteolysis was stopped by adding EDTA to give a
final concentration of 15 mM. Aliquots of the incubation mixtures were added to macrophage foam cells, and
other aliquots of the remainders were delipidated (Scanu, 1966) for mass analysis of the cleavage products.
Proteolysis of HDL3 and plasma by granule remnants and subsequent quantification of preβ1-HDL
particles (III)
   To measure [3H]cholesterol efflux, samples of fresh plasma (5%) were incubated at 37 °C for 90 min with
[3H]cholesterol-loaded macrophages in the presence of increasing quantities of granule remnants. The foam
cells were then washed with PBS, and addition of fresh plasma to the cultures started a second 90-minute
efflux period. In a separate experiment, samples of native HDL3 (1 mg/ml) or fresh plasma (17.5 mg/ml)
were incubated at 37 °C for the indicated time periods of up to 24 h in the presence of granule remnants.
Control incubations were performed either in the presence of granule remnants at 4 °C, or in the absence of
granule remnants at 37 °C. The incubations were stopped by centrifugation at 4 °C, 15 000 rpm for 5 min,
and the samples were frozen immediately and kept at -70 °C until analyzed by 2D-PAGGE. Finally, 5% fresh
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plasma was preincubated for 6 h at 4 °C (native) or at 37 °C (preβ-HDL-depleted). Both samples of plasma
were then incubated at 37 °C with [3H]cholesterol-loaded macrophages in the presence or absence of granule
remnants, and the levels of radioactivity of the media were measured after 90 min.
6. Efflux from macrophage foam cells
Measurement of [3H]cholesterol efflux from macrophage foam cells (I-IV)
   [3H]Cholesterol-loaded macrophages were washed with PBS, and the cells were immersed in DMEM
(Gibco) with 100 U/ml penicllin and 100 µg/ml streptomycin. Cholesterol acceptors were added to give the
final concentrations indicated in the figure legends of the original papers, and the mixtures were incubated at
37 °C for 6 h in a humidified 5% CO2
 
incubator in the presence or absence of mast cell granule remnants. In
some cases, the cholesterol efflux-inducing ability of samples preincubated with granule remnants was
determined. After incubation, the media were collected and centrifuged at 200 x g for 5 min to remove any
detached cells or cellular debris, and the 3H radioactivity in the supernatant was measured by liquid scintillation
counting. Thin-layer chromatography showed that most (95%) of the radioactivity was present in the free
cholesterol fraction. From each value, the corresponding blank value (medium without acceptor) was subtracted.
The linearity of  [3H]cholesterol efflux was tested with the highest concentration of acceptor particles. In
every case, efflux was found to be linear (see II, Fig. 1).
Net cholesterol transfer (I, II, III)
   To study the net efflux (mass movement of cholesterol) from cholesterol-loaded macrophages, macrophage
monolayers were loaded with LDL-cholesterol by incubating them in the same conditions as above, except
that unlabeled acetyl-LDL was used. After incubation with acceptor particles at 37 °C for 6 h or 24 h (mouse
macrophages) or for 12 h (human monocyte-derived macrophages), the monolayers were washed, cholesterol
was extracted from the cells with hexane:isopropanol (3:2 v/v), and the quantity of cellular cholesterol obtained
was determined by a fluorometric assay (Gamble et al., 1978) or HPLC (Araki et al., 1990; Piha et al.,
1995). For protein measurements, the macrophages were then treated with 0.2 N NaOH. The incubations
were carried out in triplicate.
7. Analysis of proteolyzed HDL
Release of trichloroacetic acid-soluble material from 125I -HDL3 by granule remnants (I)
   In a standard assay, 1 mg/ml of 125I -HDL3
 
(500-8 000 cpm/µg) was incubated with 170 µg/ml of granule
remnants in 150 mM NaCl-1 mM EDTA- 5 mM Tris, pH 7.4, at 37 °C for 30 min. The granule remnants
were then centrifuged at 20 000 g for 5 minutes, and the supernatants were treated with 10% trichloroacetic
acid to determine the amount of trichloroacetic acid-soluble radioactivity. To study the inhibitory effect of
serum or intimal fluid on the granule remnants, on isolated chymase, and on α-chymotrypsin (Sigma) (each
containing 170 BTEE U/ml), the mixtures were then incubated in the presence of the indicated concentrations
of serum or aortic intimal fluid.
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Two-dimensional electrophoresis of HDL3 and plasma (III)
   Native HDL3
 
and plasma samples were analyzed for their contents of apoAI-, apoAII-, and apoAIV-
containing lipoproteins by 2D-PAGGE in the sequence: agarose gel electrophoresis, polyacrylamide gradient
gel electrophoresis, and immunoblotting (Huang et al., 1993; Huang et al., 1995a; Huang et al., 1995b; von
Eckardstein et al., 1995b). To quantify preβ1-HDL  (III), plasma was separated only by agarose gel
electrophoresis before its proteins were blotted onto nitrocellulose, ApoAI-containing particles were
immunodetected  and the intensity of immunostaining was quantified by photoimaging (BAS 1500, Fuji).
Size exclusion chromatography (IV)
   HDL3 was passed through a Superose 12 column (HR 10/30, Amersham Pharmacia Biotech) at room
temperature. A degassed solution of 150 mM NaCl, 1 mM EDTA, 5 mM Tris, pH 7.4, was used as eluent,
with a flow rate of 0.4 ml/min by the SMART system.
N-terminal sequencing (IV)
   Protein samples were separated in a 15% SDS-PAGE followed by electroblotting onto a ProBlott PVDF
membrane in 10 mM CAPS (3-cyclohexylamino-1-propane-sulfonic acid), pH 11, containing 10% methanol
(Matsudaira, 1987). Proteins were visualized by staining with Coomassie brilliant blue, and bands of interest
were cut out and loaded onto the sequencer (494 HT Procise Protein Sequencer, Applied Biosystems)
which determines the sequence of amino acids in a protein according to Edman degradation procedure.
Mass spectrometry (IV)
   Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry was performed
on a BiflexTM time-of-flight instrument (Bruker-Franzen Analytik) equipped with a nitrogen laser operating
at 337 nm. The delipidated HDL3 and the MMP-generated degradation products of HDL3 proteins were
analyzed in the linear positive ion delayed extraction mode, using sinapic acid (a saturated solution in 0.1%
trifluoroacetic acid, 30% acetonitrile) (Aldrich) as the matrix. Samples were prepared by dissolving the
delipidated HDL3 (20µg) in 100µl of 0.1% trifluoroacetic acid, 30% acetonitrile, and mixed 1:1 with matrix
solution. One µl of the mixture was spotted on the target plate and dried in a stream of warm air. All mass
spectra were calibrated internally, using the [M+H] + and [M+2H]2+ signals (m/z 28080.0 and 14040.5,
respectively) of apoAI.
8. Statistical analysis
    Statistical analysis was carried out using Student’s t test for paired samples. Any test yielding a P value of
< 0.05 was taken to indicate a statistically significant difference. Analyses of variance, ANOVA, (Friedman’s
2-way, or parametric 2-way) and repeated measures of ANOVA were also used for specific experiments as
described in each case.
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RESULTS
CHOLESTEROL EFFLUX FROM MACROPHAGE FOAM CELLS
1. Effect of proteolysis of HDL3
 
on its ability to promote cholesterol efflux from
macrophage foam cells
   To generate [3H]cholesteryl ester-containing foam cells, human monocyte-derived macrophages or mouse
peritoneal macrophages were incubated with [3H]CL-acLDL 25 µg/ml for 48 h or 20 µg/ml for 18 h,
respectively. During incubation, the contents of cholesteryl esters in the human and mouse macrophages
increased from ~3 to ~90 µg and ~4 to ~70 µg/ mg cell protein, respectively. Subsequent incubation of the
cells with all the acceptors studied here resulted in a constant rate of efflux of 3H-radioactivity into the
incubation medium for at least 12 h, and a time interval of 6 h was chosen for the standard efflux experiments.
Cholesterol efflux-blocking factor of mast cells (I)
   When mast cells were added to the culture medium of mouse macrophage foam cells and stimulated with
compound 48/80, that the mast cells decreased the ability of HDL3 to induce cholesterol efflux was evident
within 1 h. Thereafter, only a minimal rate of cholesterol efflux could be detected. The effect was not exerted
on the foam cell membrane components, for subsequent addition of fresh HDL3 to the foam cells promoted
efflux virtually identical to that from untreated foam cells. Moreover, when mast cell-pretreated incubation
media containing HDL3 were added to fresh foam cells, the efflux of [3H]cholesterol from these foam cells
was reduced significantly.
   The granule remnants of the mast cells were found to be responsible for the cholesterol efflux-blocking
effect: 125I -HDL3 incubation at 37 °C for 30 minutes with granule remnants isolated from stimulated mast
cells led to degradation of 6% of the total radioactivity of the radiolabeled apolipoproteins, as measured by
the formation of 125I-labeled trichloroacetic acid-soluble products. After incubation, the granule remnants
were sedimented. No cosedimentation of the 125I-HDL3 was observed, indicating that the HDL3 particles
were not bound to the granule remnants. Inhibition studies of the two main proteases of rat serosal mast cell
granule remnants, chymase and carboxypeptidase A, showed that the proteolytic modification of the HDL3
particles leading to reduced efflux of cholesterol was due to granule chymase; inhibition  of chymase prevented
proteolysis of HDL3, which then retained its cholesterol efflux-promoting ability. In granule remnant-modified
HDL3 particles, the contents of unesterified cholesterol, cholesterol esters, phospholipids, and triglycerides
remained unchanged. Moreover, no thiobarbituric acid-reactive material was formed during incubation of
HDL3 with granule remnants. Finally, neither HDL3 aggregates nor uptake of 125I -HDL3 or of granule
remnant-treated 125I -HDL3 by the foam cells were found. Taken together, the above experiments demonstrated
that what rendered HDL3 less effective in inducing efflux of radiolabeled cholesterol from macrophage foam
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 cells was the proteolytic degradation of HDL3 by the neutral protease chymase in the exocytosed mast cell
granules.
Effect of MMPs on the ability of HDL to promote cholesterol efflux (IV)
   To study the effect of MMPs on HDL-mediated cholesterol efflux, HDL3
 
 was preincubated with MMPs of
different types and the variously treated HDL3
 
preparations were added to human or mouse macrophage
foam cells. After pretreatment with MMP-3, -7, and -12 (stromelysin and stromelysin-like MMPs) for only
30 min, HDL3
  
lost 80% of its ability to induce cholesterol efflux. In contrast, the effect of MMP-1 (collagenase)
on the efflux-inducing function of HDL3 was much weaker, since the rate of cholesterol efflux was significantly
reduced only after 72 h. MMP-9 (gelatinase) treatment did not decrease the cholesterol efflux-promoting
ability of HDL3. The results show that proteolysis of HDL3 by stromelysin or stromelysin-like MMPs
causes a greater decrease in HDL3-mediated cholesterol efflux than the other MMP subclasses.
2. High-affinity component of cholesterol efflux
Serum, plasma, and lipoprotein-deficient serum (II, III)
   [3H]Cholesterol-loaded macrophage foam cells were incubated for 6 h in media containing various
concentrations of human serum, and the efflux of [3H]cholesterol from the cells into the  medium was measured
(II, Fig. 1A). As the concentration of the serum increased, the rate of cholesterol efflux from the foam cells
increased rapidly to a steady level at a serum protein concentration of about 2.5 mg/ml. Addition of granule
remnants to the incubation medium led to a sharp decrease in cholesterol efflux from the foam cells, especially
at a low serum concentration, suggesting a high-affinity component responsible for the rapid efflux when the
serum concentration was low. In the presence of granule remnants, cholesterol efflux increased almost linearly
with the serum concentration. Results similar to the above were obtained when human blood plasma (containing
the thrombin inhibitor D-phe-pro-arg chloromethyl ketone, PPACK) was used instead of human serum: As
the concentration of serum increased, the rate of cholesterol efflux from the foam cells increased rapidly to a
steady level and, on addition of granule remnants to the incubation medium, the rate of cholesterol efflux
from the macrophages decreased sharply.
   When lipoproteins were removed from the serum by prior ultracentrifugation (at d=1.25 g/ml), the rate of
cholesterol efflux was reduced (II, Fig. 1B). This difference was especially pronounced at low serum protein
concentrations. Similarly, in apoAI-deficient serum, the rate of cholesterol efflux was considerably lower
than in whole serum from human or mouse macrophage foam cells (Figs. 3A and 3B). When granule remnants
were added to lipoprotein-deficient serum, the rate of cholesterol efflux was reduced still further, being a
linear function of the protein concentration within the range of protein concentrations studied.  In contrast,
addition of granule remnants to apoAI-deficient serum had no effect on its ability to induce cholesterol efflux.
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Lipoproteins (I, II)
   To identify the efflux-inducing serum components sensitive to the proteolytic action of granule remnant
chymase, we isolated lipoprotein fractions from serum by ultracentrifugation and further immunopurification
of VHDL on an anti-apoAI affinity column, and tested their ability to induce [3H]cholesterol efflux from
macrophage foam cells in the absence and presence of proteolytically active granule remnants (II, Fig. 2).
The VLDL+IDL (d=1.006-1.019 g/ml) fraction showed only a slight cholesterol efflux-promoting effect, and
this effect was blocked by the granule remnants. The LDL (d=1.019-1.063 g/ml) fraction showed only an
insignificant cholesterol efflux-promoting effect. In contrast, on addition of fractions of HDL to the incubation
medium, the rate of cholesterol efflux increased sharply, with increasing concentrations, up to about 25 µg/
ml of HDL, and then more slowly. VHDL (d=1.21-1.25 g/ml) and HDL3
 
(d=1.125-1.210 g/ml) were almost
identical in their cholesterol-promoting activities, and HDL2 (d=1.063-1.125 g/ml) was somewhat less effective.
Incubation of the various HDL subclasses with granule remnants greatly reduced their abilities to induce
[3H]cholesterol efflux; all three HDL subclasses so treated induced  similar low levels of cholesterol efflux.
Kinetic analysis of HDL3
 
data indicated that the reduction in the rate of cholesterol efflux resulted from both
a decrease in the apparent Vmax values of the efflux system and an apparent decrease in the affinity of HDL3
for this system. The apparent Vmax and Km values for control and granule-remnant-treated HDL3 were
1000 dpm versus 450 dpm/µg mouse macrophage cell protein, and 23 versus 45 µg/ml, respectively (I, Fig.
4B).
   When LpAI particles (comprizing both LpAI w AII and LpAI w/o AII particles) isolated from serum were
incubated with cholesterol-loaded mouse or human macrophages in the presence or absence of granule remnants,
the results were similar to those obtained with HDL3
 
(II, Fig.4). Thus, when the concentration of LpAI was
increased, the rate of cholesterol efflux rose and, on addition of granule remnants, LpAI-induced cholesterol
efflux from both cell types was strongly inhibited to the same low level.
Preβ-mobile HDL in plasma (III)
   The preβ1-HDL level in plasma has been shown to fall after incubation at 37 °C, this reduction being
dependent on LCAT activity (Miida et al., 1992). To study the proportion of cholesterol efflux from macrophage
foam cells that was due to preβ-HDL, plasma was preincubated for 6 h at 37 °C to obtain preβ1-HDL-
deficient plasma. Depletion of the preβ1-HDL particles in plasma resulted in a significant reduction in its
cholesterol-promoting activity as compared with that of plasma preincubated for 6 h at 4 °C (III, Table 3).
When fresh plasma (5%) was incubated with [3H]cholesterol-loaded macrophages in the presence of as little
as 6 µg of granule remnants, this was enough to reduce the cholesterol efflux activity of plasma significantly.
Addition of 15 µg of granule remnants to the incubation medium reduced cholesterol efflux by approximately
50% (III, Fig. 4) and the latter granule remnant concentration was used in this experiment.When the two
preincubated plasmas were incubated with cholesterol-loaded foam cells in the presence of granule remnants,
their cholesterol efflux capacities were reduced still further (III, Table 3). As expected, the granule remnant-
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dependent reduction was more pronounced and significant in those plasma samples that had been preincubated
at 4 °C. The result reveals the susceptibility of preβ-HDL particles to proteolytic attack by chymase and the
significant role of this subpopulation in plasma in promoting cholesterol efflux from cells.
Preβ-mobile particles in HDL3 (III, IV)
   HDL3 was separated by size exclusion chromatography on a Superose 12 column into major and minor
HDL3 peaks (IV, Fig.3A). The material eluted as a minor peak had preβ-mobility and contained apoAI. The
ability of these particles  to induce cholesterol efflux from human monocyte-derived foam cells was slightly
less than half (1750 dpm, 2 µg/ml) of that of bulk HDL3 (3990 dpm, 20 µg/ml) (IV, Table 1). The ability of
the material in the minor peak to cause efflux was particularly high, considering that in the HDL3
 
 fraction
the mass ratio of the small particles to the major HDL3 was 1:10. This result also demonstrated that, despite
its high specific activity, the material eluting in the minor peak did not account for the full efflux capacity of
the HDL3 fraction. Furthermore, treatment of the material from the minor and the major peaks with MMP-
3 reduced their abilities to induce cholesterol efflux to similar extents.
Aortic intimal fluid (II)
   Finally, to study whether the observed residual proteolytic activity of the granule chymase in intimal fluid
was sufficient to inhibit the cholesterol efflux-promoting activity of intimal fluid (case 6), we incubated
cholesterol-loaded human monocyte-macrophages in intimal fluid and measured the rate of cholesterol efflux
(II, Fig. 8). When increasing amounts (up to 2.5%; v/v) of intimal fluid were present in the incubation
medium, the efflux of cholesterol from the loaded human monocyte-macrophages at first rose sharply and
then more slowly. When the intimal fluid had been pretreated with granule remnants, the high-affinity component
of the efflux was eliminated.
3. Ability of granule remnants to degrade HDL3 in the presence of serum or aortic
intimal fluid (II)
   The ability of granule remnants to proteolytically inactivate the cholesterol efflux-promoting components
of serum revealed that, in the presence of the natural protease inhibitors of serum or plasma, the activity of
granule remnant chymase was not fully inhibited. In the granule remnants, chymase is embedded in a heparin
proteoglycan matrix, where it is tightly bound to heparin glycosaminoglycan chains (Kido et al., 1985). To
investigate whether these structures protect chymase from inhibition, we compared the ability of chymase
released from the matrix to resist natural protease inhibitors. For comparison, we also used α-chymotrypsin,
an endopeptidase with specificity similar to chymase. The proteolytic activities of granule remnant-bound
chymase, isolated chymase, and α-chymotrypsin (each 170 BTEE units/ml) were determined by measuring
the production of TCA-soluble material from 125I-HDL3
 
 in the absence and presence of 10% serum (II, Fig.
5). In the absence of serum, the granule remnant-bound chymase and isolated chymase degraded HDL3 at
roughly equal rates, but less rapidly than α-chymotrypsin. When serum was added to the incubation system,
42
Results
the activities of isolated chymase and α-chymotrypsin were both almost totally blocked. However, the ability
of the granule remnants to proteolyze 125I-HDL3 was inhibited by only about 50%, so leaving significant
residual proteolytic activity in the presence of serum.
   
125I-HDL3 was incubated in increasing concentrations of aortic intimal fluid with granule remnant-bound
chymase and isolated chymase. In each of the four cases studied, intimal fluid strongly inhibited the proteolytic
activity of isolated chymase, inhibition being total when the proportion of intimal fluid reached 16% (II, Fig.
6). At the same concentration of intimal fluid, inhibition of granule remnant-bound chymase was much
weaker and varied considerably from case to case. Even at the highest concentration of intimal fluid used (64
vol%), inhibition was not total, the remaining activity ranging from 10 to 50% of the control values observed
in the absence of intimal fluid.
4. Effect of proteolysis of apoAI and apoAII on their ability to promote cholesterol
efflux from macrophage foam cells (II, III, IV)
   HDL3 was divided by immunoaffinity chromatography into two fractions according to the apolipoprotein
content: particles containing apoAI and apoAII, and particles containing apoAI, but no apoAII. Particles of
both types promoted cholesterol efflux from [3H]cholesterol-loaded human monocyte-macrophages and, in
both cases, the efflux was reduced by  addition of granule remnants (II, Table 1). Proteolysis of apoAII
without apparent proteolysis of apoAI by MMPs-2 and -9 (gelatinases) had no effect on HDL3-mediated
cholesterol efflux.
   Addition of lipid-free apoAI (up to 100 µg) to the cholesterol-loaded mouse macrophage foam cells resulted
in a rapid increase in the radioactivity of the medium until a protein concentration of approximately 6 µg/ml
was reached and thereafter less rapidly until a steady level was reached at a protein concentration of
approximately 25 µg/ml. Addition of granule remnants to the incubation system greatly reduced the ability of
apoAI to remove cholesterol from cells, especially at low concentrations. Essentially the same results were
observed when isolated apoAI was preincubated with human chymase and then added to human monocyte-
derived macrophage foam cells (III, Table 1) and when purified apoAI was treated with MMP-7 (IV, Fig. 4)
5. Net cholesterol transfer (I, II, III)
   Determination of the cellular cholesteryl ester content of mouse macrophage foam cells revealed that the
acceptors which induced efflux of tritium cholesterol (serum, LPDS, HDL2, HDL3, VHDL, LpAI, and
apoAI) were also able to induce net of cholesterol from the foam cells for up to 12 h (II, Table 2; III, Table 2).
In each case, moreover, treatment with proteolytically active granule remnants significantly reduced the
acceptor-induced net efflux of cholesterol. Accordingly, apoAI-deficient serum did not promote net cholesterol
efflux from macrophage foam cells either with or without granule remnant treatment. Human monocyte-
derived macrophages also released cholesterol when incubated with HDL3, and this net efflux was
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significantly reduced if the HDL3 had been pretreated with mast cell granule remnants (II, Table 2).
EFFECT OF PROTEOLYSIS ON HDL STRUCTURE
6. Analysis of chymase- or MMP-proteolyzed HDL
Proteolysis of HDL3 sufficient to block cholesterol efflux from foam cells (I,IV)
   Incubation of 125I - HDL3 in the presence of granule remnants resulted in its progressive degradation. The
effect of proteolysis on the cholesterol-promoting activity of HDL3 was already significant at a minimal
proteolytic modification of 125I -HDL3 (<4% degradation of the total radioactivity) with the granule remnants,
which led to reduction of cholesterol efflux to about half of the control. Further proteolysis of HDL3 decreased
its ability to promote cholesterol efflux still further, but no longer so dramatically, leading maximally to 70-
80% inhibition of cholesterol efflux. Such minimal degradation of HDL3 left the apolipoproteins (AI and
AII) of HDL3 visually unaltered when analyzed by SDS-PAGE. In agarose gel electrophoresis, the mobility
of HDL3 was unchanged when a lipid stain was used.
   SDS-PAGE analysis of MMP-treated HDL3 revealed degradation of apoAI during incubation with MMP-
3, -7, or -12, i.e., with the enzymes that inhibited HDL3-dependent cholesterol efflux from foam cells (IV,
Fig. 6). These enzymes degraded apoAI (28 kDa) to forms with apparent Mrs of 24-26 kDa and to smaller
fragments of approximately 14 and 6 kDa. In contrast, when HDL3 was incubated with MMP-1, degradation
products appeared much less rapidly. However, there was again a certain discrepancy between the inhibition
of cholesterol efflux and the degree of proteolysis of HDL3: 70% loss of cholesterol efflux from foam cells
was not a consequence of such a great loss of apolipoproteins in HDL3. In contrast, SDS-PAGE analysis of
the minor peak of Superose 12 gel filtration after treatment with MMP-3 showed almost complete degradation
of the apoAI (IV, Fig. 5). In cellulose acetate electrophoresis, the only change in HDL3
 
proteolyzed by
chymase or MMPs-1,-3, -7, or 12 as compared with native HDL3, was the disappearance of the minor preβ-
mobility band.
   Proteolysis did not change the contents of total cholesterol or phospholipid (data not shown). Nor was it
dependent on LCAT, since inhibition of LCAT during proteolysis by MMP-7 did not have any further effect
on efflux. The HDL3 samples had neither PLTP nor CETP activity.
Effect of proteolysis on HDL3 particles of different sizes (III, IV)
   2D-PAGGE analysis after granule remnant treatment showed the disappearance of small-sized preβ1-HDL
particles from the bulk HDL3. Treatment with MMP-3, -7, or -12, i.e. with those MMPs that had caused loss
of the cholesterol efflux-inducing capacity of HDL3, also resulted in the disappearance of the small particles,
as shown by size-exclusion chromatography (IV, Fig.3A).  MMP-1, which had only a slight effect on the
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cholesterol efflux-inducing capacity of HDL3
, 
caused a slight retention in the elution of the small particles,
reflecting an apparent decrease in their size. But MMP-9, which did not reduce the cholesterol efflux-inducing
capacity of HDL3
, 
also failed to reduce the quantity of small particles.
2D-PAGGE analysis of plasma proteolyzed by mast cell chymase (III)
   2D-PAGGE analysis revealed that plasma treated with granule remnants suffered a time-dependent and
progressive loss of preβ1-HDL and LpAIV-1 particles (the smaller of the two LpAIV subpopulations).
Incubation of plasma with granule remnants at 37 °C for 1 h led to the disappearance of LpAIV-2 as well, but
after incubation for a longer time, this change was independent of the presence of chymase. Densitometric
analysis of anti-apoAI immunoblots of agarose gels revealed that, even after incubation with granule remnants
for as little as 5 and 15 minutes at 37 °C, 60% of the preβ1-HDL had disappeared, and 90% had disappeared
after incubation for 24 h. Treatment of plasma with granule remnants did not change the immunoelectrophoretic
profile of apoAII-containing particles.
Proteolysis of apoAI and apoAII (II, IV)
   Western blot analysis of serum or aortic intimal fluid samples that were treated with mast cell granule
remnants showed that the granule remnant samples contained, not only intact apoAI, but also fragments with
estimated molecular weights ranging from ~ 10 to 26 kDa (II, Fig 5A). After treatment with granule remnants,
a new band, with an estimated molecular mass of 10 kDa, became visible in the Western blot of apoAII (Fig.
5B). On SDS-PAGE analysis, proteolysis of HDL3 by MMPs showed that efflux-decreasing MMPs (MMPs-
3, -7, and -12) degraded apoAI, but not apoAII. In contrast, MMP-1 appeared to degrade apoAII in addition
to apoAI, whereas MMP-9, which did not decrease HDL3-induced cholesterol efflux, appeared to degrade
only apoAII. A similar degradation pattern was seen with another gelatinase, MMP-2, which also failed to
decrease HDL3-induced cholesterol efflux significantly after incubation with HDL3 for 72 h (not shown).
SDS-PAGE analysis suggested that apoAII proteolysis alone does not significantly reduce the HDL3-induced
cholesterol efflux from macrophage foam cells.
Sites of cleavage of apoAI by MMPs (IV)
   The major fragments of apoAI (14-26 kDa) from the MMP-3, -7, and -12-treated samples of HDL3 were
all found to have the N-terminal sequence of apoAI (asp-glu-pro-pro-gln…) intact, thus confirming that, with
these MMPs, breakdown of apoAI occurs at its C-terminus. Using strategies based on MALDI-TOF mass
spectrometry combined with N-terminal sequencing, we identified the first MMP cleavage sites in apoAI that
produce fragments larger than 14 kDa. Major signals from mass analysis of MMP-3, -7, and -12-treated
HDL3 are given in Table V (IV, Table 2). Particles from the minor peak of small-sized particles (Superose 12
gel filtration) resulted in a mass spectrum for MMP-3  identical to that of MMP-3-treated total HDL3. In
sharp contrast, free apolipoprotein AI isolated from lipoproteins was rapidly degraded by MMP-3 without
apparent preference for cleavage sites (not shown).
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Fragment mass Counterpart mass
Observed Assignment Calculated Calculated Observed
MMP-3 28080 D1-Q243 28080 - -
22220 D1-E191 22223 5875 5876
14723 D1-E125 14727 13371
MMP-7 28079 D1-Q243 28080 - -
24650 D1-D213 24645 3453
23452 D1-T202 23462 4636 4640
14259 D1-P121 14259 13839
MMP-12 28079 D1-Q243 28080 - -
25989 D1-F225 25998 3453
24637 D1-D213 24645 4938 4937
23155 D1-H199 23160 5875 5876
22211 D1-E191 22223 13839
14254 D1-P121 14259
           Table V Fragmentation of apoAI by MMPs-3, -7, and -12
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DISCUSSION
1. Cholesterol efflux from macrophage foam cells caused by proteolyzed HDL
Cholesterol efflux from foam cells caused by serum, plasma, or aortic intimal
fluid treated with chymase
   The present study demonstrates the ability of exocytosed mast cell granules to modify serum, plasma, and
aortic intimal fluid proteolytically, and so prevent them from effectively promoting cholesterol efflux from
macrophage foam cells. Two components of the cholesterol efflux mechanism could be identified, one protease-
sensitive and the other protease-insensitive (Fig. 3). The protease-sensitive component increased sharply to a
saturation level at a low serum total protein concentration; this component was designated the “high-affinity
cholesterol efflux-promoting component” of serum. Removal of apoAI-containing particles from serum was
accompanied by simultaneous loss of the capacity for high-affinity efflux and of the protease sensitivity of
the serum, showing that the protease-sensitive serum component responsible for the high-affinity efflux
contained apolipoprotein AI. The result was similar when HDL2, HDL3, VHDL, or a suspension of apoAI-
containing particles was used instead of serum. The lipoprotein-deficient serum (d>1.25), which still contained
free apoAI, possessed a smaller amount of the high-affinity efflux-promoting component, which was protease-
sensitive. Thus, proteolysis by the exocytosed mast cell granules  incapacitated the components of serum that
were most closely associated with cholesterol efflux from cells (de la Llera Moya et al., 1994).
Figure 3. High-and low-affinity components that
promote cholesterol efflux from foam cells.
HDL promotes cholesterol efflux from macrophage
foam cells (total cholesterol efflux). When HDL is
exposed to chymase or MMPs, only a small proportion
of its cholesterol-promoting ability is left (low-affinity
cholesterol efflux; protease-insensitive). After
subtraction of low-affinity cholesterol efflux from total
cholesterol efflux, the remainder, shown as a dashed
line, represents the high-affinity cholesterol efflux that
is protease sensitive.
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   Extensive proteolysis of serum or aortic intimal fluid by mast cell granules led to degradation of apoAI and
to lesser extent, also of apoAII. Extensive treatment of the HDL3 with either trypsin or pronase led to
modification of the HDL3 particles, which thereafter contained no detectable intact apoAII and only small
amounts of intact apoAI, and whose ability to promote cholesterol efflux from cholesterol-loaded fibroblasts
was simultaneously greatly reduced (Oram et al., 1991). Similarly, incubation of HDL3 with human
polymorphonuclear leukocytes, which led to proteolytic cleavage of apoAII and changes in the distribution of
apoAI isoforms, decreased the ability of HDL3
 
to promote cholesterol efflux from Fu5AH rat hepatoma cells
and J774 mouse macrophages (Cogny et al., 1996). In our study, however, there was no change in apoAII-
containing lipoproteins in 2D-PAGGE after cholesterol- efflux decreasing proteolysis of plasma by chymase.
Moreover, proteolysis of apoAII alone by gelatinases did not decrease cholesterol efflux from macrophage
foam cells, revealing that, in our preparations, the key apolipoprotein promoting cholesterol efflux from cells
is apoAI. Oram’s group has shown that even mild trypsin treatment, by proteolysing a minor trypsin-labile
fraction of HDL, almost completely abolished apolipoprotein-mediated efflux of cholesterol (Mendez and
Oram, 1997). In our studies, similarly, the initial minor proteolysis had the greatest impact on the decrease in
cholesterol efflux from macrophage foam cells, suggesting the involvement of small subpopulations. In our
study, chymase also proteolysed apoAIV.  In the currently available literature there are no earlier reports of
the effect of proteolysis of apoAIV on cholesterol efflux from cells.
   Incubation of plasma at 37°C with granule remnants produced a progressive reduction in the contents of
both preβ1-HDL and LpAIV and in cholesterol efflux ability. In agreement with our previous notion that
mast cell granule remnants destroy the high-affinity cholesterol efflux-promoting component present in serum,
we found that the cholesterol efflux-reducing effect of the granule remnants was greater in plasma rich in
preβ1-HDL than in plasma poor in preβ1-HDL. Moreover, mast cell granule remnants effectively prevented
the high-affinity cholesterol efflux that is promoted by the preβ1-HDL particles generated during the incubation
of free apoAI with cholesterol-loaded macrophages. Addition of granule remnants completely abolished the
saturable high-affinity component involved in cholesterol efflux, which is found at rather low levels of apoAI
(<25 µg/ml). The residual chymase-insensitive component responsible for cholesterol efflux may have been
produced by an aqueous diffusion mechanism, which we suggest to be unaffected by whether or not apoAI is
intact.
   Incubation with granule remnants decreased the content of preβ1-HDL in plasma, but less rapidly than that
of HDL3. This difference may be attributed to the partial inhibition of granule chymase by the protease
inhibitors that are present in plasma. However, despite this partial inhibition, chymase effectively reduced the
content of preβ1-HDL during incubation for 1 h, and, after incubation for 24 h, practically all the preβ1-
HDL had disappeared from the plasma samples. The resistance of the proteolytic activity of granule remnants
to protease inhibitors was only partial and, in aortic intimal fluid samples, was highly variable. The reason
for this variation has not yet been elucidated. In one sample of intimal fluid (case 5), we found that the
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concentration of α1-antitrypsin was 1mg/ml, which is 40% of that found in serum, a result which accords
with that of Smith (1990). Moreover, the two other proteinase inhibitors to which chymase is sensitive, α2-
macroglobulin and α1-antichymotrypsin, are likely to be filtered into extracellular fluids such as the intimal
fluid. Thus, the actual degree to which chymase is inhibited in the intimal fluid appears likely to depend on the
concentrations of the various protease inhibitors in this body fluid. Most importantly, in both cases the
capacity of intimal fluid to induce cholesterol efflux from human macrophage foam cells was significantly
lowered. Degradation of the apolipoproteins of HDL3 by less than 5% was found to be sufficient to impede
the cholesterol efflux-promoting ability of these particles; thus, even the low residual activity of granule
chymase in the intimal fluid may be sufficient to block HDL-mediated cholesterol efflux.
Cholesterol efflux from macrophage foam cells caused by HDL treated with chymase
or MMPs
   Proteases blocked the high-affinity efflux of cholesterol from serum; moreover, they also destroyed the
efflux-promoting abilities of the different HDL density classes. Even minimal proteolysis of HDL by mast
cell chymase strongly inhibited the ability of HDL to promote cholesterol efflux. VHDL and HDL3 had
almost identical cholesterol efflux-promoting activities which underwent greater reduction when treated with
mast cell chymase than the corresponding activity of HDL2, which was somewhat less affected, especially at
lower concentrations (<50 µg/ml). Incubation of HDL3 with granule remnants at 37°C produced progressive
reductions in both the content of preβ1-HDL and the ability to promote cholesterol efflux. When HDL3 was
incubated with granule remnants for as little as 30 minutes, no preβ-mobile particles were observed, revealing
that the rapid rate of inhibition was connected with the high efficiency of the proteolytic degradation. The
most susceptible substrates for the cholesterol-efflux-decreasing MMPs were, as with chymase, the small
HDL particles with preβ-mobility.
2. Proteolysis of HDL
Proteolysis of minor subpopulations of HDL3 by MMPs
   The great loss of cholesterol efflux-promoting ability did not require extended proteolysis of apoAI. This
unexpected finding is not due to changes in the lipid composition of these particles for, in the modified HDL3
particles, the contents of total cholesterol and phospholipid remained unchanged (data not shown). Nor is it
dependent on functional LCAT, since inhibition of LCAT during proteolysis by MMP-7 did not have any
further effect on efflux. The HDL3 samples had neither PLTP nor CETP activity. Finally, HDL3 was not
oxidatively modified during incubations with chymase. 2D-PAGGE showed that HDL3 contained small
amounts of preβ1-HDL and similarly, after Superose 12-gel filtration, we found that the HDL3
 
fraction
contained minor amounts of small particles which, on cellulose acetate electrophoresis, showed preβ-mobility.
The small particles disappeared very rapidly during treatment with cholesterol efflux-reducing MMPs (MMPs-
3,-7, and -12) or chymase. Importantly, this loss of the small particles was accompanied by reduction of the
high-affinity component of cholesterol efflux from the macrophage foam cells. The apoAI has been shown to
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be more susceptible to proteolysis in the preβ fraction than in the α-HDL particles (Kunitake et al., 1990).
We found that, after incubation with MMP-3 for as little as 15 min, 90% of the intact apoAI in the small
particles had been converted into 22 kDa-sized fragments. In the case of MMPs, although the loss of the
small particles accords well with the rapid inhibitory effect of these MMPs on the cholesterol efflux-inducing
ability of  HDL3, we cannot exclude the possibility that  changes were present in other subfractions of the
ultracentrifugally isolated HDL3 as well, but were not detected by the methods used in this study. A more
complete analysis of the proteolyzed subpopulations and correlation with the loss of the cholesterol efflux-
promoting capacity of HDL3 requires additional experiments.
   The preβ-mobile fraction appeared to be in a state of balance with the major HDL3 fraction. In fact, after
separation of these two fractions by gel filtration, we repeatedly observed the appearance of a peak containing
the small particles in addition to the major HDL3 peak. Even multiple re-isolation of the major peak failed to
produce a fraction without a preβ band. Only HDL3 that had been floated through a KBr solution (1.21 g/ml)
using high g forces (424 000 x g, 16 h) and was analyzed immediately after re-isolation, showed pure α-
mobility. But, after dialysis, a preβ band soon reappeared (regeneration within 4 h) reflecting the tendency of
apoAI to dissociate from the spherical particles with α-mobility (data not shown). Whether apoAI dissociates
spontaneously or in response to trace amounts of preβ-generating enzymes in HDL (PLTP or CETP) cannot
be resolved here. It has been demonstrated that PLTP restores the cholesterol efflux affinity of mildly trypsinated
HDL (Wolfbauer et al., 1999). This effect required cellular interaction, but the mechanism is not known.
Since we were unable to detect PLTP or CETP activity in the HDL3 preparations, it is likely that apoAI
dissociated spontaneously from the major HDL3 fraction. This notion accords with the suggestion of Mendez
and Oram (1997) that the apolipoproteins in HDL that are most sensitive to proteolysis are likely to be less
tightly bound to phospholipids, and therefore can dissociate more easily from the particle surface and mediate
cholesterol efflux. From the present findings, we infer that the MMPs preferentially proteolyze the apoAI
molecules, which readily dissociate from the α-HDL particles and form preβ-mobile particles. Although the
quantity of preβ-mobile particles in the HDL3 preparations was very small, their regeneration would make
them potentially significant cholesterol acceptors. Since preβ-HDL particles are considered to be the first
acceptors of cellular free cholesterol (Castro and Fielding, 1988), degradation of the preβ-mobile particles
and, in particular, inhibition of their regeneration could significantly contribute to the observed inhibition of
the cholesterol efflux-inducing ability of HDL3 by the MMPs (Fig. 4).
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Figure 4. Proteolysis of preβ-particles and
potential inhibition of generation of preβ-
particles from α-HDL by chymase and
MMPs.
Chymase and MMPs readily reduce the preβ-
HDL subfraction to a degradation product that
is no longer able to promote cholesterol efflux.
In addition, chymase and MMPs block the
regeneration (dissociation) of preβ-mobile
particles from α-HDL. These processes are
illustrated in Fig. 5 in a more physiological
environment (the arterial intima).
   The disappearance of protein from the position of preβ1-HDL particles in 2D-PAGGE and on Superose 12
gel filtration after treatment with proteases shows that the cleaved peptides did not remain attached to the
particles after cleavage. Cholesterol efflux into the C-terminal peptide (209-241) has been shown to be
approximately 70% of that into intact lipid-free apoAI (Gillotte et al., 1999). Since, in our experiment,
cholesterol efflux decreased dramatically after the first cleavage, it is inconceivable that the C-terminal
peptide is released into the medium, where it would be able to interact with the cell membranes. Rather, it
seems that, after the first cleavages at the C-terminus, the C-terminal peptide may then be rapidly proteolysed
further. Enrichment of the N-terminal 14 kDa fragment observed in SDS-PAGE suggests that the N-terminal
half of apoAI is less susceptible to proteolysis by MMPs than the C-terminal half. The proteolyzed fragments
of apoAI may also have inhibited the removal of cholesterol by bulk HDL3. To test this possibility, we mixed
intact HDL3 either with the entire MMP-7-treated HDL3 or with the MMP-7-treated minor peak of  HDL3,
and added these two mixtures separately to macrophage foam cells. As compared with the ability of intact
HDL3 alone to induce cholesterol efflux, the effects of the mixtures were in both cases additive, revealing
that neither the proteolyzed HDL3 as a whole nor the proteolyzed minor peak inhibited the activity of intact
HDL3 (data not shown).
Proteolysis of the C-terminus of apoAI
   The matrix metalloproteinases acted chiefly on the C-terminal region of apoAI. The first degradation
products split off by these enzymes, which reduce HDL3-induced cholesterol efflux, are 22-26 kDa fragments,
and correspond to losses of the final 18-52 amino acids (see Table 3). Similarly, mast cell chymase proteolyzes
apoAI from the C-terminal end (M. Lee, unpublished observation). This susceptibility of the C-terminus to
proteolysis accords with previous findings in which limited degradation by other enzymes (chymotrypsin,
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trypsin, elastase, subtilisin, staphylococcus V8 protease, and arginine C endopeptidase) produced 22, 24,
and 26 kDa N-terminal fragments of apoAI (Kunitake et al., 1990; Dalton and Swaney, 1993; Ji and Jonas,
1995). PLTP was also reported to have inherent protease activity toward lipid-poor apoAI and was shown to
cleave lipid-poor apoAI in the C-terminal region (Jauhiainen et al., 1999). The physiological relevance of
proteolysis of apoAI by PLTP is unknown at the moment.
   The similarities in kinetics between the degradation of apoAI and the loss of the reverse cholesterol transport
activity of HDL3 particles suggest that apoAI was already inactivated by these first cleavages in the C-
terminal region. Similarly, Marcel and Frank (1998), using lipid-free or lipidated human apoAI mutants,
concluded that the C-terminal domain of apoAI is especially important for promoting cholesterol efflux from
cholesterol-loaded macrophages. Another study using lipid-free apoAI mutants reported that induction of
phospholipid efflux and subsequent cholesterol efflux from HepG2 cells requires the presence of the 21 C-
terminal amino acids (Sviridov et al., 1996b). The C-terminus has also been shown to be essential for the
structural integrity of the adjacent regions of apoAI (Pyle et al., 1996). Similarly, studies with the natural
apoAI variants (Pro165 →Arg and Glu235→0) have shown that these variants of apoAI are poor acceptors of
cholesterol from adipocytes and macrophages (von Eckardstein et al., 1993; Luchoomun et al., 1994; Han et
al., 1999). Von Eckardstein and coworkers (1993) suggested that the pro→arg substitution in position 165
eliminates a β turn between two adjacent α-helices and so changes the orientation of all subsequent α-helices.
Since these mutational changes in the C-terminal portion of apoAI lead to structural changes in the adjacent
parts of the molecule, it has not been possible to determine whether the reduction in cholesterol efflux is
caused by changes in the C-terminus itself or by secondary effects on the residual apoAI molecule. Similarly,
we cannot decide whether the event responsible for the observed functional changes was cleavage of the C-
terminal region of apoAI or possible secondary changes in apoAI structure.
   The C-terminal part of apoAI has also been shown to be important for binding to the plasma membrane
binding sites for apoAI (Morrison et al., 1992; Barbaras et al., 1994). This binding was suggested to trigger
intracellular cholesterol transport from intracellular pools to the plasma membrane (Mendez et al., 1991).
Proteolysis of the plasma membrane was shown to destroy these binding sites (Kawano et al., 1993; Li et al.,
1995). Thus, it may be that proteolysis of apoAI (and apoAIV) destroys the structural domains of apoAI (and
apoAIV) that are required for this specific interaction.
3.  Proteolysis of apoAI or apoAIV and proposed mechanisms of cholesterol efflux from
cells
   Two main mechanisms of cholesterol efflux have been proposed, aqueous diffusion and apoAI-dependent
cholesterol efflux (Rothblat et al., 1999). Since aqueous diffusion, in which net cholesterol efflux is driven by
a cholesterol gradient, is considered to be an ineffective process, apoAI-dependent cholesterol efflux from
cells seems likely to be the only significant mechanism in a cholesterol-enriched interstitial fluid such as the
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aortic intimal fluid. The synergistic effect of small particles which are tranporters of cholesterol with larger
particles acting as cholesterol sinks would also accord well with our system. The small preβ1-HDL or
LpAIV-1 are good cholesterol acceptors and their proteolysis decreases cholesterol efflux dramatically.
However, the minor peak (having preβ mobility), when isolated from bulk HDL3, was not able to account for
the total cholesterol efflux. It is possible that the major, larger HDL serves as a sink into which preβ1-HDL
or LpAIV-1 transports the cholesterol, acting either like a shuttle between the cholesterol membrane and the
larger HDL particles or by fusing to larger HDL particles. Thus, the preβ1-HDL and LpAIV particles together
with α-HDL may account for the high-affinity cholesterol efflux-promoting component and when preβ1-
HDL and LpAIV particles are degraded and generation of preβ-mobile particles is prevented, the remaining
α-HDL particles alone are able to promote only low cholesterol efflux from foam cells, probably by the
mechanism of aqueous diffusion (see Fig. 3).
   Proteolysis of the plasma membrane by trypsin and proteinase K was shown to prevent binding of apoAI to
it, and accordingly to decrease cholesterol efflux from the cell (Morrison et al., 1992; Kawano et al., 1993; Li
et al., 1995). Proteolysis of apoAI by chymase and MMPs probably destroys the corresponding site in
apoAI. It has been suggested, on the basis of Tangier disease, that only cell-derived lipids are essential for the
production of mature HDL from lipid-poor apoAI, indicating interaction of apoAI with the plasma membrane
(Young and Fielding, 1999). Since the most important part of apoAI in lipid binding the is C-terminal, lipid-
poor apoAI is suggested to be dependent on this region during cholesterol efflux from the plasma membrane.
4. Physiological relevance of proteolysis of apoAI in the aortic intima
Proteolysis of apoA by chymase
   Recent observations that the numbers of degranulated mast cells are higher in the foam cell-containing
areas of the human aorta (Kaartinen et al., 1994a) and coronary arteries (Kaartinen et al., 1994b) would
suggest that, in the atherosclerosis-prone areas of the arterial wall, mast cells can alter the delicate balance
between cholesterol influx and efflux and so contribute to the formation and maintenance of foam cells in
these vulnerable intimal areas.
   The protease inhibitors present in the plasma or the intimal fluid, though they could block the proteolysis of
HDL by free chymase, could not completely block the proteolysis of HDL by rat mast cell chymase bound to
granule remnants. Thus, it seems that chymase, when bound to the heparin proteoglycans in granule remnants,
remains active against HDL3 despite the presence of its natural inhibitors. An association between rat chymase
and heparin proteoglycans has also been shown to protect the enzyme against protease inhibitors when acting
on a small synthetic substrate (Pejler and Berg, 1995). The small extent of proteolysis necessary to disturb
the function of HDL as a cholesterol acceptor suggests that mast cell granule chymase can proteolytically
block cholesterol efflux in the arterial intima even in the presence of its physiological inhibitors.
   Treatment of apoAI with purified skin chymase (derived from human mast cells present in the skin) also
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inhibited the transfer of cholesterol induced by the apolipoprotein from human monocyte-derived macrophage
foam cells, suggesting that chymase-containing human mast cells, when activated, may prevent apoAI from
accepting cholesterol from human foam cells. However, in unfractionated human heart homogenates, in
which chymase is likely heparin-bound, chymase activity against angiotensin I is strongly inhibited in the
presence of interstitial fluid (Kokkonen et al., 1997). Thus, the reason for this apparent difference in the
sensitivity to physiological protease inhibitors between rat and human chymases in preparations of different
origin, whether due to differences in the preparative procedures, in the substrates, or in the heparin, must
await further study. It has been proposed that lipids may increase the activity of chymase (McEuen et al.,
1998). Whether this lipid-modifying effect is relevant in the aortic intima, where the lipid content is high, is
not known.
Proteolysis of apoA by MMPs
   Several members of the MMP family are able to degrade human HDL3, thereby dramatically decreasing its
capacity to promote cholesterol efflux from cholesterol-loaded human monocyte-macrophages. MMPs-3, -7,
and -12, which have broad substrate specificity (Kähäri and Saarialho-Kere, 1997), were the most efficient
in degrading apoAI; MMP-1, which has a more restricted substrate specificity, cleaved apoAI less efficiently,
and MMP-9, which also has restricted substrate specificity, was unable to degrade apoAI even during prolonged
incubation.
   Three reports have shown caseinolytic and gelatinolytic activity in atherosclerotic areas (Galis et al., 1994;
Johnson et al., 1998; Zaltsman et al., 1999). Although the concentrations of MMPs in the interstitial fluid of
atherosclerotic lesions are unknown, the MMP concentrations have been measured in synovial fluids from
arthritic joints, which, like atherosclerotic lesions, are inflammation-prone areas. Thus, in the synovial fluid
of patients with rheumatoid arthritis, the concentrations of MMPs-1, -8, and -9 ranged from 1-15 µg/ml
(Bläser et al., 1996), that of MMP-3 ranged from 6-110 µg/ml, with a mean concentration of 40 µg/ml
(Walakovits et al., 1992). Importantly, synovial fluid from patients with rheumatoid arthritis demonstrated
levels of active MMP-3 that were 100-fold higher than synovial fluid from control subjects (Beekman et al.,
1997). We performed additional experiments in which the MMP concentration in the incubation medium was
progressively lowered, and found that incubation of HDL3 with as little as 2.5 µg/ml of trypsin-activated
MMP-3 (i.e. about 1/10 of that used in the other experiments) for 20 h at 37 °C was sufficient for maximal
reduction of the efflux-promoting ability of HDL3
 
from mouse macrophage foam cells. Our results with mast
cell chymase also revealed that even a minute degree of proteolysis of HDL3 can cause a dramatic decrease
in its ability to promote cholesterol efflux from macrophage foam cells.  It is also important to note that the
foam cells in the atherosclerotic lesions themselves produce MMPs (Henney et al., 1991; Matsumoto et al.,
1998), and that some of the MMPs secreted by the cell remain attached to the cell membrane during cell
migration (Leppert et al., 1995). Thus, in the pericellular compartment on or near the cell membrane, the
local concentration of MMPs is likely to be high. To be able to induce cholesterol efflux, apoAI has to come
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into very close contact with or be attached to the cell membrane. It appears likely that the concentration of
MMPs in relation to that of apoAI is much higher near the cell membrane than in the bulk of the extracellular
fluid in the arterial intima, and the concentration of (active) MMPs would then be adequate to prevent apoAI-
dependent cholesterol efflux from the macrophage foam cells in atherosclerotic lesions.
   Intimal amyloid deposits are often associated with atherosclerotic plaque. The intimal amyloid has been
shown to react histochemically with antiserum to apoAI, although only partly and to varying degrees
(Amarzguioui et al., 1998). Interestingly, SDS-PAGE analysis of a major fibril protein purified from amyloid
deposits in the aortic intima revealed two broad bands corresponding to ~14 and < 10 kDa, which were
shown to be N-terminal fragments of apoAI (Westermark et al., 1995). Mutations of apoAI with an extra
positive charge in the N-terminal half have been shown to enhance amyloidogenicity (systemic amyloidosis),
with deposits of N-terminal fragments (residues 1- 83 to 1-94) (Genschel et al., 1998). Recently, an apoAI
mutation outside the N-terminal peptide (apoAI variant Leu174→Ser) has also been shown to deposit amyloid
fibrils (aa residues 1-93) principally in the heart (Obici et al., 1999). This variant was also associated with
lower HDL and apoAI plasma levels, which may be associated with known accelerated plasma catabolism of
C-terminal truncated apoAI (Schmidt et al., 1995; Han et al., 1999). The mechanism by which these fragments
were generated is unknown. One possibility is by degradation of apoAI by proteases in the intima. In our in
vitro studies, proteolysis of apoAI by matrix metalloproteinases led to the formation of fragments of ~14
kDa, and these fragments seemed to be enriched during proteolysis. It is an intriguing possibility that such
fragments may become enriched and be deposited in the atherosclerotic intima. Moreover, it has been shown
that wild-type apoAI is amyloidogenic, but mutant apoAI-forms are associated with enhanced amyloidogenicity.
Whether these apoAI variants are more prone to proteolysis or whether is it the extra positive charge in the N-
terminal part that causes their enhanced deposition after proteolysis remains a challenging physiological
question.
Proteolysis of preβ1-HDL and LpAIV subpopulations of HDL
   Preβ1-HDL was shown to be the initial cellular cholesterol acceptor (Castro and Fielding, 1988). In the
case of apoAI deficiency, apoAIV and apoE (γLpE) have been suggested to replace the action of preβ1-HDL
(von Eckardstein et al., 1995a; von Eckardstein et al., 1995b). The extravascular fluids are relatively enriched
in these particles. Thus, their proteolysis, and the consequent inhibition of cholesterol efflux, may be of
special importance in the arterial intima, where the concentration of LDL cholesterol is high and foam cells
are formed. Since macrophages cannot regulate the influx of cholesterol, the only way to maintain the cholesterol
balance in these cells is by efflux. The extremely sensitive proteolytic depletion of preβ1-HDL  and LpAIV
suggests that extracellular proteolysis plays a role in the control of the earliest step in the removal of cholesterol
from the arterial intima, and that mast cell chymase and matrix metalloproteases may promote foam cell
formation in the intima (Fig. 5).
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Figure 5. Schematic presentation of the possible effect of proteolysis on the ability of apoAI to
promote cholesterol efflux from macrophage foam cells in the arterial intima.
α-HDL particles as well as lipid poor apoAI enter the aortic intima. In the intimal fluid, lipid-poor
apoAI (preβ1-HDL) dissociates from α-HDL. The small preβ1-HDL particles promote cholesterol
efflux from macrophage foam cells (left), and the discs formed (preβ2-HDL) leave the intima, penetrating
through the internal elastic lamina to the lymphatics in the inner media. When apoAI is proteolyzed by
the chymase expelled from mast cells or by the MMPs secreted by smooth muscle cells, endothelial
cells, or macrophage foam cells, its ability to accept cholesterol from foam cells is lost. This blockage
of cholesterol efflux contributes to cholesterol accumulation in macrophage foam cells.
   Elucidation of the effects of the matrix metalloproteinases and chymase, and possibly of other proteases, on
apoAI and its cholesterol efflux-promoting and other antiatherogenetic properties remains an important
challenge for future studies. The proteolytic modifications of apoAI may turn out to be of major importance
in blocking the physiological functions of apoAI in the arterial intima, such as mediation of the initial steps of
reverse cholesterol transport from human atherosclerotic lesions consisting of numerous macrophage-derived
foam cells.
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5. Other proteases potentially capable of blocking HDL-mediated cholesterol efflux
   Several other proteolytic enzymes are secreted by cells present in the arterial intima (i.e. macrophages,
smooth muscle cells, and T lymphocytes), and these proteases could also potentially act on apoAI (and
apoAII and apoAIV) (Jonasson et al., 1986; Kramer and Simon, 1987; Mitchinson and Ball, 1987; Seydewitz
and Staubesand, 1988). In addition, stimulated mast cells secrete not only chymase, but also tryptase and
cathepsin G (Welle, 1997). Furthermore, plasmin, thrombin, and kallikrein, three plasma-derived enzymes
that have also been found in the arterial intima (Nolly et al., 1993; Tanaka and Sueishi, 1993), have also been
shown to cleave apoAI (Kunitake et al., 1990). In addition, increased expression of cathepsin S and K is
found in atheromatous tissues (Sukhova et al., 1998). It remains to be shown which of these proteolytic
enzymes are present in active form in the intimal fluid. The present findings emphasize the importance of
studying the enzymes in their physiological form (e.g. chymase bound to granule heparin), rather than when
isolated or purified. For example also plasmin is protected from its natural inhibitors only when bound to
specific receptors on cellular (or bacterial) surfaces (Lottenberg et al., 1994).
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SUMMARY AND CONCLUSIONS
   Foam cells are formed when modified LDL is taken up by macrophages in such amounts that cholesterol
efflux from cells to acceptor (HDL) particles cannot counterbalance the influx. This may be due not only to
increased influx, but also to impaired efflux. In these studies, we have investigated the effects of chymase and
matrix metalloproteinases, which are found in the aortic intima, on the ability of HDL to promote cholesterol
efflux from macrophage foam cells.
   Mast cell chymase proteolyzed lipoproteins in serum and human aortic intimal fluid and prevented these
two fluids from effectively inducing cholesterol efflux from cultured macrophage foam cells. Inhibition was
strongest when chymase was added to apolipoprotein AI-containing lipoprotein (HDL), resulting in
disappearance of the high-affinity component of the cholesterol efflux; chymase had no effect on the weaker
efflux produced by apoAI-deficient serum. In plasma, the subpopulations of HDL most susceptible to proteolysis
by mast cell chymase were found to be preβ1-HDL and LpAIV-1 and -2. The disappearance of these particles
from plasma did not affect the distribution of apoAII-containing lipoproteins or α-migrating particles in
plasma. When HDL3 was treated with mast cell chymase, 2D-PAGGE analysis showed depletion of preβ1-
HDL particles in this chymase-treated HDL3.
   When treated with matrix metalloproteinases -3, -7, and -12, HDL3 had strongly reduced ability to promote
cholesterol efflux from macrophage foam cells, whereas MMP-1 reduced HDL3-mediated cholesterol efflux
only slightly, and MMP-9 had no effect. Treatment of HDL3 with MMPs decreased cholesterol efflux from
human macrophage foam cells by approximately 70%, a change that was not accompanied by such extensive
degradation of bulk HDL3, but reflected the ability of MMPs to degrade the small preβ-migrating particles
present in the HDL3 fraction. NH2-terminal sequence and mass spectrometric analyses of the apoAI  fragments
generated by MMPs revealed that those MMPs that strongly reduced cholestrol efflux (MMPs-3, -7 and -12)
cleaved the COOH-terminal region of apoAI and produced a major fragment of about 22 kDa, whereas
MMPs-1 and -9, which had little and no effect on cholestrol efflux, degraded  apoAI only slightly and not at
all, respectively.
   Extravascular fluids are relatively enriched in preβ1-HDL and LpAIV particles, which are both efficient
cellular cholesterol acceptors. Thus, extracellular proteolysis of preβ1-HDL and apoAIV-1 and -2 by the
various neutral proteases present in the intimal fluid, with consequent inhibition of cholesterol efflux, may be
of special importance in the arterial intima, the site of atherogenesis.
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